



**GUIDELINES ON GOOD MANUFACTURING PRACTICES FOR
ACTIVE PHARMACEUTICAL PRODUCTS
PART 2**

MARCH, 2023

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04/2026
Revision No.: 2	Approval date:06/04/2023	Effective Date:12/04/2023

FOREWORD

Rwanda Food and Drugs Authority (Rwanda FDA) is a regulatory body established by the Law N° 003/2018 of 09/02/2018 determining its mission, organization and functioning. One of its main powers is to formulate regulations and Guidelines for regulating the manufacture of Pharmaceutical products to ensure that they comply with quality standards required for good manufacturing practices.

Considering the provisions of the regulations N° FDISM/FDIC/TRG/005, governing Good Manufacturing Practices for medical products. The Authority issues the Guidelines N° FDISM/FDIC/GDL/010 Good Manufacturing Practice for Active Pharmaceutical Products - Part 2.

Badly manufactured Pharmaceutical products effects are one of the public health concerns not only to our country but also all over the world. It is in this context that the Rwanda Food and Drugs Authority intends to put in place Guidelines that provide for good manufacturing practices of Pharmaceutical products to ensure that manufactured medicines do not constitute harmful effects to people's health that leads to losses of life.

It is expected that these Guidelines will offer a clear understanding to manufacturers and other persons concerned by the Guidelines during the evaluation process; they will protect consumers and pharmaceutical manufacturing industry, thus promoting health protection, business as well as the national economy as a whole.

Dr. Emile BIENVENU
Director General



Digitally signed
by Rwanda FDA
(Director General)
Date: 2023.04.06
10:19:12 +02'00'

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

GUIDELINES DEVELOPMENT HISTORY

DRAFT ZERO BY RWANDA FDA	01/09/2021
STAKEHOLDERS CONSULTATION	28/09/2021
ADOPTION OF STAKEHOLDERS' COMMENTS	30/09/2021
DATE FOR COMING INTO EFFECT	12/04/2023

DOCUMENT REVISION HISTORY

Date of revision	Revision number	Changes made and/or reasons for revision
04/10/2021	0	First issue
14/09/2022	1	1. Adding the types of inspection, qualification of key personnel, classification of inspection findings and updated GMP certificate 2. Amendment of requirements for GMP application
29/03/2023	2	1. Chapter 2: 2.1 Types of inspection Updated the Types of inspection from “pre-approval” to “Routine” and updated the text and added another type referred to as “Any type of Inspection” as deemed necessary by the Authority

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

TABLE OF CONTENTS

GUIDELINES DEVELOPMENT HISTORY	3
DOCUMENT REVISION HISTORY	3
TABLE OF CONTENTS	4
ABBREVIATIONS AND ACRONYMS	6
1.1 Purpose of these Guidelines.....	16
1.2 Policy	16
1.3 Scope.....	16
CHAPTER 2: GOOD MANUFACTURING PRACTICE INSPECTION.....	18
2.1Types of inspections	18
2.2Application for GMP	19
3.2Quality Risk Management	20
3.3Responsibilities of the Quality Unit(s)	20
3.4Responsibility for Production Activities	21
3.5Internal Audits (Self Inspection)	22
3.6Product Quality Review.....	22
4.1General.....	23
4.2Key personnel	23
4.3Personnel Hygiene	27
4.4Consultants	27
CHAPTER 5: BUILDINGS AND FACILITIES	28
5.1Design and Construction.....	28
5.2Utilities.....	29
5.3Water.....	29
5.4Containment.....	30
5.5Lighting.....	30
5.6Sewage and Refuse	30
5.7Sanitation and Maintenance.....	30
CHAPTER 6: PROCESS EQUIPMENT.....	31
6.1Design and Construction.....	31
6.2Equipment Maintenance and Cleaning	31
6.3Calibration	32
6.4Computerized Systems	33
CHAPTER 7: DOCUMENTATION AND RECORDS.....	34
7.1Documentation System and Specifications	34
7.2Equipment Cleaning and Use Record.....	34
7.3Records of Raw Materials, Intermediates, API Labelling and Packaging Materials	35

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

7.4Master Production Instructions (Master Production and Control Records)	35
7.5Batch Production Records (Batch Production and Control Records).....	36
7.6Laboratory Control Records	37
7.7Batch Production Record Review	38
CHAPTER 8: MATERIALS MANAGEMENT	39
8.1General Controls	39
8.2Receipt and Quarantine.....	39
8.3Sampling and Testing of Incoming Production Materials	40
8.4Storage.....	40
8.5Re-evaluation.....	41
9.1Production Operations	41
9.2Time Limits	42
9.3In-process Sampling and Controls.....	42
9.4Blending Batches of Intermediates or APIs.....	43
CHAPTER 12: LABORATORY CONTROLS.....	47
CHAPTER 13: VALIDATION	51
CHAPTER 15: REJECTION AND RE-USE OF MATERIALS	56
CHAPTER 16: COMPLAINTS AND RECALLS	57
CHAPTER 17: CONTRACT MANUFACTURERS (INCLUDING LABORATORIES).....	58
CHAPTER 19: SPECIFIC GUIDANCE FOR APIS MANUFACTURED BY CELL CULTURE/FERMENTATION.....	61
CHAPTER 20: APIS FOR USE IN CLINICAL TRIALS	65
ENDORSEMENT OF THE GUIDELINES	68
ANNEXES	69

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

ABBREVIATIONS AND ACRONYMS

API:	Active Pharmaceutical Ingredient
CAPA:	Corrective Actions and/or Preventive Actions
GMP:	Good Manufacturing Practices
HVAC:	Heating, Ventilation and Air Conditioning
ICH:	International Council for Harmonization
OOS:	Out-Of-Specification
PIC/S:	Pharmaceutical Inspection Cooperation Scheme
QA:	Quality Assurance
QC:	Quality Control
SOP:	Standard Operating Procedures

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

GLOSSARY

“Acceptance Criteria.” numerical limits, ranges, or other suitable measures for acceptance of test results;

“Action limit” established criteria, requiring immediate follow-up and corrective action if exceeded;

“Active Pharmaceutical Ingredient (API) (or Drug Substance)” any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure and function of the body;

“Authorized person” is a person recognized by the authority as having the necessary basic scientific and technical background and experience. Authorized person(s) is responsible for the release of batches of finished product for sale or distribution. The batch documentation of a batch of a finished product must be signed by an authorized person from the production department and the batch test results by an authorized person from the quality control department for batch release;

“Batch (or Lot)”: A specific quantity of material produced in a process or series of processes so that it is expected to be homogeneous within specified limits. In the case of continuous production, a batch may correspond to a defined fraction of the production. The batch size can be defined either by a fixed quantity or by the amount produced in a fixed time interval;

“Batch Number (or Lot Number)”: A unique combination of numbers, letters, and/or symbols that identifies a batch (or lot) and from which the production and distribution history can be determined;

“Batch numbering system”: standard operating procedure describing the details of the batch numbering;

“Batch records”: All documents associated with the manufacture of a batch of bulk product or finished product. They provide a history of each batch of product and of all circumstances pertinent to the quality of the final product;

“Bio-generator”: A contained system, such as a fermenter, into which biological agents are introduced along with other materials so as to affect their multiplication or their production of other substances by reaction with the other materials. Bio generators are generally fitted with devices for regulation, control, connection, material addition and material withdrawal;

“Bioburden” the level and type (e.g. objectionable or not) of micro-organisms that can be present in raw materials, API starting materials, intermediates or APIs. Bioburden should not be considered contamination unless the levels have been exceeded or defined objectionable organisms have been detected;

“Biological agents” microorganisms, including genetically engineered microorganisms, cell cultures and endoparasites, whether pathogenic or not;

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

“Bulk product” Any product that has completed all processing stages up to, but not including, final packaging;

“Calibration” the demonstration that a particular instrument or device produces results within specified limits by comparison with those produced by a reference or traceable standard over an appropriate range of measurements;

“Cell bank system” a cell bank system is a system whereby successive batches of a product are manufactured by culture in cells derived from the same master cell bank (fully characterized for identity and absence of contamination). A number of containers from the master cell bank are used to prepare a working cell bank. The cell bank system is validated for a passage level or number of population doublings beyond that achieved during routine production;

“Cell culture” results from the in-vitro growth of cells isolated from multicellular organisms;

“Certification” the final review and formal approval of a validation or revalidation, followed by approval of a process for routine use;

“Clean area” an area with defined environmental control of particulate and microbial contamination, constructed and used in such a way as to reduce the introduction, generation and retention of contaminants within the area;

“Computer System” a group of hardware components and associated software, designed and assembled to perform a specific function or group of functions;

“Computerized System” a process or operation integrated with a computer system;

“Consignment (or delivery)” the quantity of starting material, or of a drug product, made by one manufacturer and supplied at one time in response to a particular request or order. A consignment may comprise one or more packages or containers and may include material belonging to more than one batch;

“Contained systems” an area constructed and operated in such a manner (and equipped with appropriate air handling and filtration) so as to prevent contamination of the external environment by biological agents from within the area;

“Containment” the action of confining a biological agent or other entity within a defined space;

“Contamination” the undesired introduction of impurities of a chemical or microbiological nature, or of foreign matter, into or onto a raw material, intermediate, or API during production, sampling, packaging or repackaging, storage or transport;

“Contract Manufacturer” a manufacturer performing some aspect of manufacturing on behalf of the original manufacturer;

“Controlled area” an area constructed and operated in such a manner that some attempt is made to

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

control the introduction of potential contamination (an air supply approximating to grade D may be appropriate), and the consequences of accidental release of living organisms. The level of control exercised should reflect the nature of the organism employed in the process. At a minimum, the area should be maintained at a pressure negative to the immediate external environment and allow for the efficient removal of small quantities of airborne contaminants;

“Critical process” a process that may cause variation in the quality of the pharmaceutical product;

“Critical” describes a process step, process condition, test requirement, or other relevant parameter or item that must be controlled within predetermined criteria to ensure that the API meets its specification;

“Cross-Contamination” contamination of a material or product with another material or product;

“Crude plant (vegetable drug)” fresh or dried medicinal plant or parts thereof;

“Cryogenic vessel” a container designed to contain liquefied gas at extremely low temperature;

“Cylinder” a container designed to contain gas at a high pressure;

“Deviation”: departure from an approved instruction or established standard;

“Drug (Medicinal) Product” the dosage form in the final immediate packaging intended for marketing;

“Drug Substance”: see Active Pharmaceutical Ingredient;

“Exotic organism” a biological agent where either the corresponding disease does not exist in a given country or geographical area, or where the disease is the subject of prophylactic measures or an eradication program undertaken in the given country or geographical area;

“Expiry Date (or Expiration Date)” the date placed on the container/labels of an API designating the time during which the API is expected to remain within established shelf-life specifications if stored under defined conditions, and after which it should not be used;

“Finished product” a product that has undergone all stages of production, including packaging in its final container and labeling;

“Herbal medicinal products” medicinal products containing, as active ingredients, exclusively plant material and/or vegetable drug preparations;

“Impurity Profile” a description of the identified and unidentified impurities presents in an API;

“Impurity” any component present in the intermediate or API that is not the desired entity;

“In-Process Control (or Process Control)”: checks performed during production in order to

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

monitor and, if appropriate, to adjust the process and/or to ensure that the intermediate or API conforms to its specifications;

“In-process control” checks performed during production in order to monitor and if necessary, to adjust the process to ensure that the product conforms to its specifications. The control of the environment or equipment may also be regarded as a part of in-process control;

“Infected” contaminated with extraneous biological agents and therefore capable of spreading infection;

“Installation qualification” the performance of tests to ensure that the installations (such as but not limited to machines, measuring devices, utilities, manufacturing areas) used in a manufacturing process are appropriately selected and correctly installed and operate in accordance with established specifications;

“Intermediate” is a material produced during steps of the processing of an API that undergoes further molecular change or purification before it becomes an API. Intermediates may or may not be isolated. (Note: this Guide only addresses those intermediates produced after the point that the company has defined as the point at which the production of the API begins);

“Manifold” equipment or apparatus designed to enable one or more gas containers to be filled simultaneously from the same source;

“Manufacture” all operations of receipt of materials, production, packaging, repackaging labelling, re-labelling, quality control, release, storage, and distribution of APIs and related controls;

“Manufacturer” a company that carries out at least one step of manufacture;

“Marketing authorization” a legal document issued by the competent Authority for the purposes of marketing or free distribution of a product which has been approved after evaluation for safety, efficacy and quality;

“Master cell bank” is a culture of (fully characterized) cells distributed into containers in a single operation, processed together in such a manner as to ensure uniformity and stored in such a manner as to ensure stability. A master cell bank is usually stored at -70°C or lower;

“Master formula” a document or set of documents specifying the starting materials with their quantities and the packaging materials, together with a description of the procedures and precautions required to produce a specified quantity of a finished product as well as the processing instructions, including the in-process controls;

“Master record” a document or set of documents that serve as a basis for the batch documentation (blank batch record);

“Master seed lot ” is a culture of a micro-organism distributed from a single bulk into containers in a single operation in such a manner as to ensure uniformity, to prevent contamination and to ensure stability. A master seed lot in liquid form is usually stored at or below -70°C. A freeze- dried master

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

seed lot is stored at a temperature known to ensure stability;

“Material” is a general term used to denote raw materials (starting materials, reagents, solvents), process aids, intermediates, APIs and packaging and labelling materials;

“Media fill” method of evaluating an aseptic process using a microbial growth medium. (Media fills are synonymous to simulated product fills, broth trials, broth fills among others);

“Medicinal plant” plants the whole or part of which is used for pharmaceutical purposes;

“Medicinal products” any medicine or similar product intended for human use, which is subject to control under health legislation in the manufacturing or importing State;

“Mother Liquor” is the residual liquid which remains after the crystallization or isolation processes. A mother liquor may contain unreacted materials, intermediates, levels of the API and/or impurities. It may be used for further processing;

“Operational qualification” documented verification that the system or subsystem performs as intended over all anticipated operating ranges;

“Packaging Material” any material intended to protect an intermediate or API during storage and transport;

“Packaging material” any material, including printed material, employed in the packaging of a pharmaceutical product, excluding any outer packaging used for transportation or shipment. Packaging materials are referred to as primary or secondary according to whether or not they are intended to be in direct contact with the product;

“Packaging” all operations, including filling and labelling, which a bulk product has to undergo in order to become a finished product;

“Pharmaceutical product” any substance capable of preventing, treating human or animal diseases and any other substance intended for administration to a human being or an animal in order to diagnose diseases, restore, correct or carry out modification of organic or mental functions. It also means products used in disinfecting premises where food and drugs are manufactured, prepared or stored, cleaning hospitals, equipment and farm houses;

“Primary containment” is a system of containment, which prevents the escape of a biological agent into the immediate working environment. It involves the use of closed containers or safety biological cabinets along with secure operating procedures;

“Procedure” a documented description of the operations to be performed, the precautions to be taken and measures to be applied directly or indirectly related to the manufacture of an intermediate or API;

“Procedures” description of the operations to be carried out, the precautions to be taken and

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

measures to be applied directly or indirectly related to the manufacture of medicinal products;

“Process Aids” materials, excluding solvents, used as an aid in the manufacture of an intermediate or API that do not themselves participate in a chemical or biological reaction (e.g. filter aid, activated carbon, among others);

“Process Control”: See In-Process Control;

“Production” all operations involved in the preparation of a medicinal product, from receipt of materials, through processing and packaging, to its completion as a finished product;

“Production” all operations involved in the preparation of an API from receipt of materials through processing and packaging of the API;

“Qualification” action of proving and documenting that equipment or ancillary systems are properly installed, work correctly, and actually lead to the expected results. Qualification is part of validation, but the individual qualification steps alone do not constitute process validation;

“Qualification” action of proving that any equipment works correctly and actually leads to the expected results. The word validation is sometimes widened to incorporate the concept of qualification;

“Quality Assurance (QA)” the sum total sum of the organized arrangements made with the object of ensuring that all APIs are of the quality required for their intended use and that quality systems are maintained;

“Quality assurance” part of quality management focuses on providing confidence that quality requirements will be fulfilled;

“Quality Control (QC)” checking or testing that specifications are met;

“Quality control” part of quality management focused on fulfilling quality requirements;

“Quality Unit(s)” an organizational unit independent of production which fulfills both quality assurance (QA) and quality control (QC) responsibilities. This can be in the form of separate QA and QC units or a single individual or group, depending upon the size and structure of the organization;

“Quality Unit(s)”an organizational unit independent of production which fulfills both Quality Assurance and Quality Control responsibilities. This can be in the form of separate QA and QC units or a single individual or group, depending upon the size and structure of the organization;

“Quarantine” the status of materials isolated physically or by other effective means pending a decision on their subsequent approval or rejection;

“Quarantine” the status of starting or packaging materials, intermediate, bulk or finished products isolated physically or by other effective means whilst awaiting a decision on their release or refusal;

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

“Radiopharmaceutical” any medicinal product which, when ready for use, contains one or more radionuclides (radioactive isotopes) included for a pharmaceutical purpose;

“Raw Material” is a general term used to denote starting materials, reagents, and solvents intended for use in the production of intermediates or APIs;

“Reconciliation” a comparison, making due allowance for normal variation, between the amount of product or materials theoretically and actually produced or used;

“Record” a document stating results achieved or providing evidence of activities performed;

“Recovery” the introduction of all or part of previous batches of the required quality into another batch at a defined stage of manufacture;

“Reference Standard, Primary” a substance that has been shown by an extensive set of analytical tests to be authentic material that should be of high purity. This standard can be: (1) obtained from an officially recognized source, or (2) prepared by independent synthesis, or (3) obtained from existing production material of high purity, or (4) prepared by further purification of existing production material;

“Reference Standard, Secondary” a substance of established quality and purity, as shown by comparison to a primary reference standard, used as a reference standard for routine laboratory analysis;

“Reprocessing” the reworking of all or part of a batch of product of an unacceptable quality from a defined stage of production so that its quality may be rendered acceptable by one or more additional operations;

“Reprocessing” introducing an intermediate or API, including one that does not conform to standards or specifications, back into the process and repeating a crystallization step or other appropriate chemical or physical manipulation steps (e.g., distillation, filtration, chromatography, milling) that are part of the established manufacturing process. Continuation of a process step after an in-process control test has shown that the step is incomplete is considered to be part of the normal process, and not reprocessing;

“Retest Date” the date when on which a material should be re-examined to ensure that it is still suitable for use;

“Return” sending back to the manufacturer or distributor of a medicinal product which may or may not present a quality defect;

“Revalidation” repeated validation of an approved process (or a part thereof) to ensure continued compliance with established requirements;

“Reworking” subjecting an intermediate or API that does not conform to standards or specifications

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

to one or more processing steps that are different from the established manufacturing process to obtain acceptable quality intermediate or API (e.g., recrystallizing with a different solvent);

“Secondary containment” is a system of containment which prevents the escape of a biological agent into the external environment or into other working areas. It involves the use of rooms with specially designed air handling, the existence of airlocks and/or sterilises for the exit of materials and secure operating procedures. In many cases it may add to the effectiveness of primary containment;

“Seed lot/Seed lot system” a seed lot system is a system according to which successive batches of a product are derived from the same master seed lot at a given passage level. For routine production, a working seed lot is prepared from the master seed lot. The final product is derived from the working seed lot and has not undergone more passages from the master seed lot than the vaccine shown in clinical studies to be satisfactory with respect to safety and efficacy. The origin and the passage history of the master seed lot and the working seed lot are recorded;

“Signature (signed)” the record of the individual who performed a particular action or review. This record can be initials, full handwritten signature, personal seal, or authenticated and secure electronic signature;

“Solvent” is an inorganic or organic liquid used as a vehicle for the preparation of solutions or suspensions in the manufacture of an intermediate or API;

“Specification” a document describing in detail the requirements with which the products or materials used or obtained during manufacture have to conform. Specifications serve as a basis for quality evaluation;

“Standard operating procedure (SOP)” an authorized written procedure giving instructions for performing operations not necessarily specific to a given product or material but of a more general nature (e.g., equipment operation, maintenance and cleaning; validation; cleaning of premises and environmental control; sampling and inspection). Certain SOPs may be used to supplement product-specific master and batch production documentation;

“Starting Material” a raw material, intermediate, or an API that is used in the production of an API and that is incorporated as a significant structural fragment into the structure of the API. An API Starting Material can be an article of commerce, a material purchased from one or more suppliers under contract or commercial agreement, or produced in-house. API Starting Materials are normally of defined chemical properties and structure;

“Sterility” s: Sterility is the absence of living organisms. The conditions of the sterility tests are given in the European (or other relevant) Pharmacopoeia;

“System” is a regulated pattern of interacting activities and techniques that are united to form an organized whole;

“Validation Protocol” a written plan stating how validation will be conducted and defining acceptance criteria. For example, the protocol for a manufacturing process identifies processing

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

equipment, critical process parameters/operating ranges, product characteristics, sampling, test data to be collected, number of validation runs, and acceptable test results; **“Validation”** is a documented program that provides a high degree of assurance that a specific process, method, or system will consistently produce a result meeting pre- determined acceptance criteria;

“Working cell bank” is a culture of cells derived from the master cell bank and intended for use in the preparation of production cell cultures. The working cell bank is usually stored at -70°C or lower;

“Working seed lot” a culture of a micro-organism derived from the master seed lot and intended for use in production. Working seed lots are distributed into containers and stored as described above for master seed lots;

“Yield, expected” the quantity of material or the percentage of theoretical yield anticipated at any appropriate phase of production based on previous laboratory, pilot scale, or manufacturing data;

“Yield, Theoretical” the quantity that would be produced at any appropriate phase of production, based upon the quantity of material to be used, in the absence of any loss or error in actual production. Sterile filling would not normally be regarded as part of packaging, the bulk product being the filled, but not finally packaged, primary containers.;

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

CHAPTER 1: INTRODUCTION

Rwanda FDA is established by the Law N° 003/2018 of 09/02/2018 determining its mission, organization and functioning. The mandate of the authority is to protect public health through regulation of human and veterinary medicines, vaccines and other biological products, processed foods, poisons, medicated cosmetics, medical devices, household chemical substances, tobacco & tobacco products.

1.1 Purpose of these Guidelines

These Guidelines are adopted from the Pharmaceutical Inspection Cooperation Scheme (PIC/S), PE 009-15 (Part II), 1st May 2021. The PIC/S Guidelines are internationally accepted Good Manufacturing Practice Guidelines.

These Guidelines are intended to provide guidance to the pharmaceutical manufacturers of Active pharmaceutical products on how to comply with Good Manufacturing Practice (GMP).

The Guidelines shall form the basis of GMP inspection by Rwanda Food and Drugs Authority (Rwanda FDA) as one of the requirements for registration of pharmaceutical products in Rwanda.

1.2 Policy

Article N° 9(1) of the Law N° 003/2018 of 09/02/2018 establishing Rwanda FDA and determining its mission, organization and functioning mandates Rwanda FDA to formulate regulations and Guidelines for regulating the manufacture, import and export, distribution, sale and use of regulated products.

One of the means of regulating manufacture of pharmaceutical products is through compliance with Good Manufacturing Practice (GMP) requirements as laid down in these Guidelines.

1.3 Scope

These Guidelines shall be used for GMP inspection of all manufacturers of APIs for medicinal products for both human and veterinary use within and outside Rwanda whose products are registered or subjected to registration in Rwanda; It applies to the manufacture of sterile APIs only up to the point immediately prior to the APIs being rendered sterile. The sterilization and aseptic processing of sterile APIs are not covered, but should be performed in accordance with the principles and Guidelines of GMP irrespective of their size, type of products, product range or location of the manufacturing facilities.

In the case of ectoparasiticides for veterinary use, other standards than this Guide, that ensure that the material is of appropriate quality, may be used.

This guidance excludes all vaccines, whole cells, whole blood and plasma, blood and plasma derivatives (plasma fractionation), and gene therapy APIs. However, it does include APIs that are produced using blood or plasma as raw materials. Note that cell substrates (mammalian, plant, insect

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

or microbial cells, tissue or animal sources including transgenic animals) and early process steps may be subject to GMP but are not covered by this guidance. In addition, the guidance does not apply to medical gases, bulk-packaged drug (medicinal) products (e.g., tablets or capsules in bulk containers), or radiopharmaceuticals.

Table 1: Application of this Guide to API Manufacturing

Type of Manufacturing	Application of this Guide to steps (shown in grey) used in this type of manufacturing				
Chemical Manufacturing	Production of the API Starting Material	Introduction of the API Starting Material into process	Production of Intermediate(s)	Isolation and purification	Physical processing, and packaging
API derived from animal sources	Collection of organ, fluid, or tissue	Cutting, mixing, and/or initial processing	Introduction of the API Starting Material into process	Isolation and purification	Physical processing, and packaging
API extracted from plant sources	Collection of plant	Cutting and initial extraction(s)	Introduction of the API Starting Material into process	Isolation and purification	Physical processing, and packaging
Herbal extracts used as API	Collection of plants	Cutting and initial extraction		Further extraction	Physical processing, and packaging
API consisting of comminuted or powdered herbs	Collection of plants and/or cultivation and harvesting	Cutting/ comminuting			Physical processing, and packaging
Biotechnology: fermentation / cell culture	Establishment of master cell bank and working cell bank	Maintenance of working cell bank	Cell culture and/or fermentation	Isolation and purification	Physical processing, and packaging
“Classical” Fermentation to produce an API	Establishment of cell bank	Maintenance of the cell bank	Introduction of the cells into fermentation	Isolation and purification	Physical processing, and packaging

Increasing GMP requirements



Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

CHAPTER 2: GOOD MANUFACTURING PRACTICE INSPECTION

2.1 Types of inspections

2.1.1 There should be four types of good manufacturing practice inspections which should be divided into the following categories:

- a. routine inspection;
- b. concise inspection;
- c. follow-up inspection;
- d. special inspection; and
- e. any other types as the Authority may designate.

2.1.2 The inspection should be conducted as follows:

- a. The routine inspection is a full inspection of all applicable components of GMP and licensing provisions. Shall be conducted at any time when the product has been registered but before expiry of validity of registration of such product. It may be indicated when the manufacturer:
 - i. Requests for renewal of a manufacturing license to operate
 - ii. Has a history on non-compliance with GMP;
 - iii. Has introduced new product lines or new products, or has made significant modifications to manufacturing methods or processes, or has made changes in key personnel, premises, equipment, etc.
 - iv. Has not been inspected during the last 3 to 5 years.
- b. Concise GMP inspections are the evaluation of limited aspects relating to GMP compliance within a facility. The manufacturers with a consistent record of compliance with GMP through previous routine inspections are eligible for concise inspections. The focus of a concise inspection is on a limited number of GMP requirements selected as indicators of overall GMP performance, plus the identification of any significant changes that could have been introduced since the last inspection. Collectively, the information obtained will indicate the overall attitude of the firm towards GMP. Evidence of unsatisfactory GMP performance observed during a concise inspection should trigger a more comprehensive inspection.
- c. Follow-up GMP inspections (reassessment or re-inspection) are made to monitor the result of corrective measures. They are normally carried out from 6 weeks to 6 months after the initial inspection, depending on the nature of the defects and the work to be undertaken. They are limited to specific GMP requirements that have not been observed or that have been inadequately implemented.
- d. Special GMP inspections may be necessary to undertake spot checks following complaints, recalls related to suspected quality defects in products or reports of adverse drug reactions.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

Such inspections may be focused on one product, a group of related products, or specific operations such as mixing, sterilization, or labeling. Special visits may be also made to establish how a specific product is manufactured as a prerequisite for marketing approval or issuance of an export certificate. A further reason for special visits to gather specific information on or to investigate specific operations and to advise the manufacturer of regulatory documents.

- e. Any other types as the Authority may designate. This may include pre-approval inspection for newly established facility.

2.2 Application for GMP

The manufacturer or applicant who intends to conduct a Good Manufacturing Practice inspection shall submit an application dossier to the Authority on the following address:

Director General
Rwanda Food and Drugs Authority
Nyarutarama Plaza, Rwanda
KG 9 Avenue, Kigali
P.O. Box 1948, Kigali, Rwanda.
E-mail : info@rwandafda.gov.rw

The requirements for application for GMP inspection of finished pharmaceutical products and active pharmaceutical ingredients manufacturing facilities are detailed in the annexes of these Guidelines. Notwithstanding the provisions above, the inspection shall not be conducted to facility which has not submitted applications for product registration.

CHAPTER 3: QUALITY MANAGEMENT

3.1 Principles

- 3.1.1 Quality should be the responsibility of all persons involved in manufacturing.
- 3.1.2 Each manufacturer should establish, document, and implement an effective system for managing quality that involves the active participation of management and appropriate manufacturing personnel.
- 3.1.3 The system for managing quality should encompass the organizational structure, procedures, processes and resources, as well as activities necessary to ensure confidence that the API will meet its intended specifications for quality and purity. All quality related activities should be defined and documented.
- 3.1.4 There should be a quality unit(s) that is independent of production and that fulfils both quality assurance (QA) and quality control (QC) responsibilities. This can be in the form of separate QA and QC units or a single individual or group, depending upon the size and structure of the organization.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

- 3.1.5 The persons authorized to release intermediates and APIs should be specified.
- 3.1.6 All quality related activities should be recorded at the time they are performed.
- 3.1.7 Any deviation from established procedures should be documented and explained. Critical deviations should be investigated, and the investigation and its conclusions should be documented.
- 3.1.8 No materials should be released or used before the satisfactory completion of evaluation by the quality unit(s) unless there are appropriate systems in place to allow for such use (e.g. release under quarantine as described in Section 8.2 or the use of raw materials or intermediates pending completion of evaluation).
- 3.1.9 Procedures should exist for notifying responsible management in a timely manner of regulatory inspections, serious GMP deficiencies, product defects and related actions (e.g. quality related complaints, recalls, regulatory actions, etc.).
- 3.1.10 To achieve the quality objective reliably there must be a comprehensively designed and correctly implemented quality system incorporating Good Manufacturing Practice, Quality Control and Quality Risk Management.

3.2 Quality Risk Management

- 3.2.1 Quality risk management is a systematic process for the assessment, control, communication and review of risks to the quality of the active substance. It can be applied both proactively and retrospectively.
- 3.2.2 The quality risk management system should ensure that:
- a. the evaluation of the risk to quality is based on scientific knowledge, experience with the process and ultimately links to the protection of the patient through communication with the user of the active substance.
 - b. the level of effort, formality and documentation of the quality risk management process is commensurate with the level of risk. Examples of the processes and applications of quality risk management can be found in Annex 2, WHO Guidelines on quality risk management.

3.3 Responsibilities of the Quality Unit(s)

- 3.3.1 The quality unit(s) should be involved in all quality-related matters.
- 3.3.2 The quality unit(s) should review and approve all appropriate quality-related documents.
- 3.3.3 The main responsibilities of the independent quality unit(s) should not be delegated. These responsibilities should be described in writing and should include but not necessarily be limited to:

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

- a. Releasing or rejecting all APIs. Releasing or rejecting intermediates for use outside the control of the manufacturing company;
- b. Establishing a system to release or reject raw materials, intermediates, packaging and labelling materials;
- c. Reviewing completed batch production and laboratory control records of critical process steps before release of the API for distribution;
- d. Making sure that critical deviations are investigated and resolved;
- e. Approving all specifications and master production instructions;
- f. Approving all procedures impacting the quality of intermediates or APIs;
- g. Making sure that internal audits (self-inspections) are performed;
- h. Approving intermediate and API contract manufacturers;
- i. Approving changes that potentially impact intermediate or API quality;
- j. Reviewing and approving validation protocols and reports;
- k. Making sure that quality related complaints are investigated and resolved;
- l. Making sure that effective systems are used for maintaining and calibrating critical equipment;
- m. Making sure that materials are appropriately tested and the results are reported;
- n. Making sure that there is stability data to support retest or expiry dates and storage conditions on APIs and/or intermediates where appropriate; and
- o. Performing product quality reviews (as defined in Section 3.6).

3.4 Responsibility for Production Activities

The responsibility for production activities should be described in writing, and should include but not necessarily be limited to:

- a. Preparing, reviewing, approving and distributing the instructions for the production of intermediates or APIs according to written procedures;
- b. Producing APIs and, when appropriate, intermediates according to pre- approved instructions;

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

- c. Reviewing all production batch records and ensuring that these are completed and signed;
- d. Making sure that all production deviations are reported and evaluated and that critical deviations are investigated and the conclusions are recorded;
- e. Making sure that production facilities are clean and when appropriate disinfected;
- f. Making sure that the necessary calibrations are performed and records kept;
- g. Making sure that the premises and equipment are maintained and records kept;
- h. Making sure that validation protocols and reports are reviewed and approved;
- i. Evaluating proposed changes in product, process or equipment; and
- j. Making sure that new and, when appropriate, modified facilities and equipment are qualified.

3.5 Internal Audits (Self Inspection)

- 3.5.1 In order to verify compliance with the principles of GMP for APIs, regular internal audits should be performed in accordance with an approved schedule.
- 3.5.2 Audit findings and corrective actions should be documented and brought to the attention of responsible management of the firm. Agreed corrective actions should be completed in a timely and effective manner.

3.6 Product Quality Review

- 3.6.1 Regular quality reviews of APIs should be conducted with the objective of verifying the consistency of the process. Such reviews should normally be conducted and documented annually and should include at least:
 - a. A review of critical in-process control and critical API test results;
 - b. A review of all batches that failed to meet established specification(s);
 - c. A review of all critical deviations or non-conformances and related investigations;
 - d. A review of any changes carried out to the processes or analytical methods;
 - e. A review of results of the stability monitoring program;
 - f. A review of all quality-related returns, complaints and recalls; and
 - g. A review of adequacy of corrective actions.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

- 3.6.2 The result of this review should be evaluated and an assessment made of whether corrective action or any revalidation should be undertaken. Reasons for such corrective action should be documented. Agreed corrective actions should be completed in a timely and effective manner.

CHAPTER 4: PERSONNEL

4.1 General

- 4.1.1 There should be an adequate number of personnel qualified by appropriate education, training and/or experience to perform and supervise the manufacture of intermediates and APIs.
- 4.1.2 The responsibilities of all personnel engaged in the manufacture of intermediates and APIs should be specified in writing.
- 4.1.3 Training should be regularly conducted by qualified individuals and should cover, at a minimum, the particular operations that the employee performs and GMP as it relates to the employee's functions. Records of training should be maintained. Training should be periodically assessed.
- 4.1.4 The manufacturer must have an organization chart in which the relationships between the heads of Production, Quality Control and where applicable Head of Quality Assurance or Quality Unit and the position of the Authorized Person(s) are clearly shown in the managerial hierarchy.
- 4.1.5 Senior management has the ultimate responsibility to ensure an effective Pharmaceutical Quality System is in place to achieve the quality objectives, and, that roles, responsibilities, and authorities are defined, communicated and implemented throughout the organization. Senior management should establish a quality policy that describes the overall intentions and direction of the company related to quality and should ensure continuing suitability and effectiveness of the Pharmaceutical Quality System and GMP compliance through participation in management review.

4.2 Key personnel

- 4.2.1 A manufacturing facility should have the following key personnel:
- a. Head of production;
 - b. Head of quality unit;
 - c. Head of quality assurance;
 - d. Head of quality control; and
 - e. Authorized person.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

- 4.2.2 Senior Management should appoint Key Management Personnel including the Head of Production, the Head of Quality Control, and if at least one of these persons is not responsible for the release of products, an authorized Person(s) shall be designated for the purpose. In large organizations, it may be necessary to delegate some of the functions of key personnel. Additionally, depending on the size and organizational structure of the company, a separate Head of Quality Assurance or Head of the Quality Unit may be appointed. Where such a function exists usually some of their responsibilities are shared with the Head of Quality Control and Head of Production and the senior management should therefore ensure that roles, responsibilities and authorities are clearly defined.
- 4.2.3 The head of production and quality control should be independent of each other.
- 4.2.4 Key posts shall be occupied by full-time personnel.
- 4.2.5 The manufacturer should notify the Authority the name of qualified and authorized person appointed by the manufacturers.
- 4.2.6 The manufacturer should notify the Authority of the name of a person to whom functions have been delegated by the responsible person and the specific functions which have been delegated to such persons.
- 4.2.7 Key personnel responsible for supervising the manufacture and quality unit including quality assurance and quality control for manufacture of pharmaceutical products should possess the qualification with scientific education and practical experience.
- 4.2.8 The head of production should have bachelor education in Pharmacy but if not, available options shall be for person with at least a bachelor education in the following:
- pharmaceutical sciences and technology;
 - chemistry (analytical or organic) or biochemistry;
 - chemical engineering;
 - Veterinary medicine.
 - Any other relevant qualification
- 4.2.9 The head of quality unit shall have bachelor education in any of the following:
- pharmacy;
 - pharmaceutical sciences and technology;
 - chemistry (analytical or organic) or biochemistry.
 - Any other relevant qualification

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

4.2.10 The head of quality control shall have bachelor education in any of the following:

- a. pharmacy;
- b. pharmaceutical sciences and technology;
- c. chemistry (analytical or organic) or biochemistry;
- d. microbiology.
- e. Any other relevant qualification

4.2.11 The heads of Production, Quality Control and where relevant, Head of Quality Assurance or Head of Quality Unit, generally have some shared, or jointly exercised, responsibilities relating to quality including in particular the design, effective implementation, monitoring and maintenance of the Pharmaceutical Quality System. These may include, subject to any national regulations:

- a. the authorization of written procedures and other documents, including amendments;
- b. the monitoring and control of the manufacturing environment;
- c. plant hygiene;
- d. process validation and calibration of analytical apparatus;
- e. training including the application and principles of quality assurance;
- f. the approval and monitoring of suppliers of materials;
- g. the approval and monitoring of contract manufacturers;
- h. the designation and monitoring of storage conditions for materials and products;
- i. the performance and evaluation in process controls;
- j. the retention of records;
- k. the monitoring of compliance with good manufacturing practice requirements;
- l. the inspection, investigation, and taking of samples, in order to monitor factors that may affect product quality.

4.2.12 The head of the production department shall have the following responsibilities:

- a. to ensure products are produced and stored according to the appropriate documentation in order to obtain the required quality;

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

- b. to approve the instructions relating to production operations, including the in- process controls and to ensure their strict implementation;
- c. to ensure that the production records are evaluated and signed by a designated person before they are made available to the quality control department;
- d. to check the maintenance of the department, premises and equipment.
- e. to ensure that the appropriate process validations and calibrations of control equipment are performed and recorded, and the reports made available;
- f. to ensure that the required initial and continuing training of production personnel is carried out and adapted according to need.

4.2.13 The head of the quality unit including quality assurance and quality control department generally shall have the following responsibilities:

- a. to approve or reject starting materials, packaging materials, and intermediate, bulk, and finished products;
- b. to evaluate batch records;
- c. to ensure that all necessary testing is carried out;
- d. to approve sampling instructions, specifications, test methods, and other quality control procedures;
- e. to approve and monitor analysis carried out under contract;
- f. to check the maintenance of the department, premises and equipment;
- g. to ensure that, appropriate validations, including those of analytical procedures, and calibrations of control equipment are done;
- h. to ensure that the required initial and continuing training of quality control personnel is carried out and adapted according to need;
- i. establish, implement and maintain the quality system;
- j. supervision of regular internal audits or self-inspections;
- k. participate in external audits; and
- l. participate in validation program.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

4.2.14 The duties of the Authorized Person(s) are described in the national requirements and can be summarized as follows:

- a. An Authorized Person must ensure that each batch of medicinal products has been manufactured and checked in compliance with the laws in force and in accordance with the requirements of the Marketing Authorization
- b. The Authorized Person(s) must meet the qualification requirements laid down in the national legislation, they shall be permanently and continuously at the disposal of the holder of the Manufacturing Authorization to carry out their responsibilities;
- c. The responsibilities of an Authorized Person may be delegated, but only to other Authorized Person(s).

4.3 Personnel Hygiene

4.3.1 Personnel should practice good sanitation and health habits.

4.3.2 Personnel should wear clean clothing suitable for the manufacturing activity with which they are involved and this clothing should be changed when appropriate. Additional protective apparel, such as head, face, hand, and arm coverings, should be worn when necessary, to protect intermediates and APIs from contamination.

4.3.3 Personnel should avoid direct contact with intermediates or APIs.

4.3.4 Smoking, eating, drinking, chewing and the storage of food should be restricted to certain designated areas separate from the manufacturing areas.

4.3.5 Personnel suffering from an infectious disease or having open lesions on the exposed surface of the body should not engage in activities that could result in compromising the quality of APIs. Any person shown at any time (either by medical examination or supervisory observation) to have an apparent illness or open lesions should be excluded from activities where the health condition could adversely affect the quality of the APIs until the condition is corrected or qualified

4.3.6 medical personnel determine that the person's inclusion would not jeopardize the safety or quality of the APIs.

4.4 Consultants

4.4.1 Consultants advising on the manufacture and control of intermediates or APIs should have sufficient education, training, and experience, or any combination thereof, to advise on the subject for which they are retained.

4.4.2 Records should be maintained stating the name, address, qualifications, and type of service provided by these consultants.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

CHAPTER 5: BUILDINGS AND FACILITIES

5.1 Design and Construction

5.1.1 Buildings and facilities used in the manufacture of intermediates and APIs should be located, designed, and constructed to facilitate cleaning, maintenance, and operations as appropriate to the type and stage of manufacture. Facilities should also be designed to minimize potential contamination. Where microbiological specifications have been established for the intermediate or API, facilities should also be designed to limit exposure to objectionable microbiological contaminants as appropriate.

5.1.2 Buildings and facilities should have adequate space for the orderly placement of equipment and materials to prevent mix-ups and contamination.

5.1.3 Where the equipment itself (e.g., closed or contained systems) provides adequate protection of the material, such equipment can be located outdoors.

5.1.4 The flow of materials and personnel through the building or facilities should be designed to prevent mix-ups or contamination.

5.1.5 There should be defined areas or other control systems for the following activities:

- a. Receipt, identification, sampling, and quarantine of incoming materials, pending release or rejection;
- b. Quarantine before release or rejection of intermediates and APIs;
- c. Sampling of intermediates and APIs;
- d. Holding rejected materials before further disposition (e.g., return, reprocessing or destruction);
- e. Storage of released materials;
- f. Production operations;
- g. Packaging and labelling operations; and
- h. Laboratory operations.

5.1.6 Adequate, clean washing and toilet facilities should be provided for personnel. These washing facilities should be equipped with hot and cold water as appropriate, soap or detergent, air driers or single service towels. The washing and toilet facilities should be separate from, but easily accessible to, manufacturing areas. Adequate facilities for showering and/or changing clothes should be provided, when appropriate.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

5.1.7 Laboratory areas/operations should normally be separated from production areas. Some laboratory areas, in particular those used for in-process controls, can be located in production areas, provided the operations of the production process do not adversely affect the accuracy of the laboratory measurements, and the laboratory and its operations do not adversely affect the production process or intermediate or API.

5.2 Utilities

5.2.1 All utilities that could impact on product quality (e.g. steam, gases, compressed air, and heating, ventilation and air conditioning) should be qualified and appropriately monitored and action should be taken when limits are exceeded. Drawings for these utility systems should be available.

5.2.2 Adequate ventilation, air filtration and exhaust systems should be provided, where appropriate. These systems should be designed and constructed to minimize risks of contamination and cross-contamination and should include equipment for control of air pressure, microorganisms (if appropriate), dust, humidity, and temperature, as appropriate to the stage of manufacture. Particular attention should be given to areas where APIs are exposed to the environment.

5.2.3 If air is recirculated to production areas, appropriate measures should be taken to control risks of contamination and cross-contamination.

5.2.4 Permanently installed pipework should be appropriately identified. This can be accomplished by identifying individual lines, documentation, computer control systems, or alternative means. Pipework should be located to avoid risks of contamination of the intermediate or API.

5.2.5 Drains should be of adequate size and should be provided with an air break or a suitable device to prevent back-siphonage, when appropriate.

5.3 Water

5.3.1 Water used in the manufacture of APIs should be demonstrated to be suitable for its intended use.

5.3.2 Unless otherwise justified, process water should, at a minimum, meet World Health Organization (WHO) Guidelines for drinking (potable) water quality.

5.3.3 If drinking (potable) water is insufficient to assure API quality, and tighter chemical and/or microbiological water quality specifications are called for, appropriate specifications for physical/chemical attributes, total microbial counts, objectionable organisms and/or endotoxins should be established.

5.3.4 Where water used in the process is treated by the manufacturer to achieve a defined quality, the treatment process should be validated and monitored with appropriate action limits.

5.3.5 Where the manufacturer of a non-sterile API either intends or claims that it is suitable for use

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

in further processing to produce a sterile drug (medicinal) product, water used in the final isolation and purification steps should be monitored and controlled for total microbial counts, objectionable organisms, and endotoxins.

5.4 Containment

- 5.4.1 Dedicated production areas, which can include facilities, air handling equipment and/or process equipment, should be employed in the production of highly sensitizing materials, such as penicillins or cephalosporins.
- 5.4.2 Dedicated production areas should also be considered when material of an infectious nature or high pharmacological activity or toxicity is involved (e.g., certain steroids or cytotoxic anti-cancer agents) unless validated inactivation and/or cleaning procedures are established and maintained.
- 5.4.3 Appropriate measures should be established and implemented to prevent cross- contamination from personnel, materials, etc. moving from one dedicated area to another.
- 5.4.4 Any production activities (including weighing, milling, or packaging) of highly toxic non-pharmaceutical materials such as herbicides and pesticides should not be conducted using the buildings and/or equipment being used for the production of APIs. Handling and storage of these highly toxic non-pharmaceutical materials should be separate from APIs.

5.5 Lighting

Adequate lighting should be provided in all areas to facilitate cleaning, maintenance, and proper operations.

5.6 Sewage and Refuse

Sewage, refuse, and other waste (e.g., solids, liquids, or gaseous by-products from manufacturing) in and from buildings and the immediate surrounding area should be disposed of in a safe, timely, and sanitary manner. Containers and/or pipes for waste material should be clearly identified.

5.7 Sanitation and Maintenance

- 5.7.1 Buildings used in the manufacture of intermediates and APIs should be properly maintained and repaired and kept in a clean condition.
- 5.7.2 Written procedures should be established assigning responsibility for sanitation and describing the cleaning schedules, methods, equipment, and materials to be used in cleaning buildings and facilities.
- 5.7.3 When necessary, written procedures should also be established for the use of suitable rodenticides, insecticides, fungicides, fumigating agents, and cleaning and sanitizing agents to prevent the contamination of equipment, raw materials, packaging/labelling materials,

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

intermediates, and APIs.

CHAPTER 6: PROCESS EQUIPMENT

6.1 Design and Construction

6.1.1 Equipment used in the manufacture of intermediates and APIs should be of appropriate design and adequate size, and suitably located for its intended use, cleaning, sanitization (where appropriate), and maintenance.

6.1.2 Equipment should be constructed so that surfaces that contact raw materials, intermediates, or APIs do not alter the quality of the intermediates and APIs beyond the official or other established specifications.

Production equipment should only be used within its qualified operating range.

Major equipment (e.g., reactors, storage containers) and permanently installed processing lines used during the production of an intermediate or API should be appropriately identified.

Any substances associated with the operation of equipment, such as lubricants, heating fluids or coolants, should not contact intermediates or APIs so as to alter their quality beyond the official or other established specifications. Any deviations from this should be evaluated to ensure that there are no detrimental effects upon the fitness for purpose of the material. Wherever possible, food grade lubricants and oils should be used.

Closed or contained equipment should be used whenever appropriate. Where open equipment is used, or equipment is opened, appropriate precautions should be taken to minimize the risk of contamination.

A set of current drawings should be maintained for equipment and critical installations (e.g., instrumentation and utility systems).

6.2 Equipment Maintenance and Cleaning

6.2.1 Schedules and procedures (including assignment of responsibility) should be established for the preventative maintenance of equipment.

6.2.2 Written procedures should be established for cleaning of equipment and its subsequent release for use in the manufacture of intermediates and APIs. Cleaning procedures should contain sufficient details to enable operators to clean each type of equipment in a reproducible and effective manner. These procedures should include:

- a. Assignment of responsibility for cleaning of equipment;
- b. Cleaning schedules, including, where appropriate, sanitizing schedules;

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

- c. A complete description of the methods and materials, including dilution of cleaning agents used to clean equipment;
- d. When appropriate, instructions for disassembling and reassembling each article of equipment to ensure proper cleaning;
- e. Instructions for the removal or obliteration of previous batch identification;
- f. Instructions for the protection of clean equipment from contamination prior to use;
- g. Inspection of equipment for cleanliness immediately before use, if practical; and
- h. Establishing the maximum time that may elapse between the completion of processing and equipment cleaning, when appropriate.

6.2.3 Equipment and utensils should be cleaned, stored, and, where appropriate, sanitized or sterilized to prevent contamination or carry-over of a material that would alter the quality of the intermediate or API beyond the official or other established specifications.

6.2.4 Where equipment is assigned to continuous production or campaign production of successive batches of the same intermediate or API, equipment should be cleaned at appropriate intervals to prevent build-up and carry-over of contaminants (e.g. degradants or objectionable levels of micro-organisms).

6.2.5 Non-dedicated equipment should be cleaned between production of different materials to prevent cross-contamination.

6.2.6 Acceptance criteria for residues and the choice of cleaning procedures and cleaning agents should be defined and justified.

6.2.7 Equipment should be identified as to its contents and its cleanliness status by appropriate means.

6.3 Calibration

6.3.1 Control, weighing, measuring, monitoring and test equipment that is critical for assuring the quality of intermediates or APIs should be calibrated according to written procedures and an established schedule.

6.3.2 Equipment calibrations should be performed using standards traceable to certified standards, if existing.

6.3.3 Records of these calibrations should be maintained.

6.3.4 The current calibration status of critical equipment should be known and verifiable.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

6.3.5 Instruments that do not meet calibration criteria should not be used.

6.3.6 Deviations from approved standards of calibration on critical instruments should be investigated to determine if these could have had an impact on the quality of the intermediate(s) or API(s) manufactured using this equipment since the last successful calibration.

6.4 Computerized Systems

6.4.1 GMP related computerized systems should be validated. The depth and scope of validation depends on the diversity, complexity and criticality of the computerized application.

6.4.2 Appropriate installation qualification and operational qualification should demonstrate the suitability of computer hardware and software to perform assigned tasks.

6.4.3 Commercially available software that has been qualified does not require the same level of testing. If an existing system was not validated at time of installation, a retrospective validation could be conducted if appropriate documentation is available.

6.4.4 Computerized systems should have sufficient controls to prevent unauthorized access or changes to data. There should be controls to prevent omissions in data (e.g. system turned off and data not captured). There should be a record of any data change made, the previous entry, who made the change, and when the change was made.

6.4.5 Written procedures should be available for the operation and maintenance of computerized systems.

6.4.6 Where critical data are being entered manually, there should be an additional check on the accuracy of the entry. This can be done by a second operator or by the system itself.

6.4.7 Incidents related to computerized systems that could affect the quality of intermediates or APIs or the reliability of records or test results should be recorded and investigated.

6.4.8 Changes to the computerized system should be made according to a change procedure and should be formally authorized, documented and tested. Records should be kept of all changes, including modifications and enhancements made to the hardware, software and any other critical component of the system. These records should demonstrate that the system is maintained in a validated state.

6.4.9 If system breakdowns or failures would result in the permanent loss of records, a back-up system should be provided. A means of ensuring data protection should be established for all computerized systems.

6.4.10 Data can be recorded by a second means in addition to the computer system

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

CHAPTER 7: DOCUMENTATION AND RECORDS

7.1 Documentation System and Specifications

- 7.1.1 All documents related to the manufacture of intermediates or APIs should be prepared, reviewed, approved and distributed according to written procedures. Such documents can be in paper or electronic form.
- 7.1.2 The issuance, revision, superseding and withdrawal of all documents should be controlled with maintenance of revision histories.
- 7.1.3 A procedure should be established for retaining all appropriate documents (e.g., development history reports, scale-up reports, technical transfer reports, process validation reports, training records, production records, control records, and distribution records). The retention periods for these documents should be specified.
- 7.1.4 All production, control, and distribution records should be retained for at least 1 year after the expiry date of the batch. For APIs with retest dates, records should be retained for at least 3 years after the batch is completely distributed.
- 7.1.5 When entries are made in records, these should be made indelibly in spaces provided for such entries, directly after performing the activities, and should identify the person making the entry. Corrections to entries should be dated and signed and leave the original entry still readable.
- 7.1.6 During the retention period, originals or copies of records should be readily available at the establishment where the activities described in such records occurred. Records that can be promptly retrieved from another location by electronic or other means are acceptable.
- 7.1.7 Specifications, instructions, procedures, and records can be retained either as originals or as true copies such as photocopies, microfilm, microfiche, or other accurate reproductions of the original records. Where reduction techniques such as microfilming or electronic records are used, suitable retrieval equipment and a means to produce a hard copy should be readily available.
- 7.1.8 Specifications should be established and documented for raw materials, intermediates where necessary, APIs, and labelling and packaging materials. In addition, specifications may be appropriate for certain other materials, such as process aids, gaskets, or other materials used during the production of intermediates or APIs that could critically impact on quality. Acceptance criteria should be established and documented for in-process controls.
- 7.1.9 If electronic signatures are used on documents, they should be authenticated and secure.

7.2 Equipment Cleaning and Use Record

- 7.2.1 Records of major equipment use, cleaning, sanitization and/or sterilization and maintenance should show the date, time (if appropriate), product, and batch number of each batch processed

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

in the equipment, and the person who performed the cleaning and maintenance.

7.2.2 If equipment is dedicated to manufacturing one intermediate or API, then individual equipment records are not necessary if batches of the intermediate or API follow in traceable sequence. In cases where dedicated equipment is employed, the records of cleaning, maintenance, and use can be part of the batch record or maintained separately.

7.3 Records of Raw Materials, Intermediates, API Labelling and Packaging Materials

7.3.1 Records should be maintained including:

- a. The name of the manufacturer, identity and quantity of each shipment of each batch of raw materials, intermediates or labelling and packaging materials for API's; the name of the supplier; the supplier's control number(s), if known, or other identification number; the number allocated on receipt; and the date of receipt;
- b. The results of any test or examination performed and the conclusions derived from this;
- c. Records tracing the use of materials;
- d. Documentation of the examination and review of API labelling and packaging materials for conformity with established specifications; and
- e. The final decision regarding rejected raw materials, intermediates or API labelling and packaging materials.

7.3.2 Master (approved) labels should be maintained for comparison to issued labels.

7.4 Master Production Instructions (Master Production and Control Records)

7.4.1 To ensure uniformity from batch to batch, master production instructions for each intermediate and API should be prepared, dated, and signed by one person and independently checked, dated, and signed by a person in the quality unit(s).

7.4.2 Master production instructions should include:

- a. The name of the intermediate or API being manufactured and an identifying document reference code, if applicable;
- b. A complete list of raw materials and intermediates designated by names or codes sufficiently specific to identify any special quality characteristics;
- c. An accurate statement of the quantity or ratio of each raw material or intermediate to be used, including the unit of measure. Where the quantity is not fixed, the calculation for each batch size or rate of production should be included. Variations to quantities should be provided they are justified;

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

- d. The production location and major production equipment to be used;
- e. Detailed production instructions, including the:
- f. Sequences to be followed,
 - i. ranges of process parameters to be used,
 - ii. sampling instructions and in-process controls with their acceptance criteria, where appropriate,
 - iii. time limits for completion of individual processing steps and/or the total process, where appropriate; and
 - iv. expected yield ranges at appropriate phases of processing or time;
 - v. Where appropriate, special notations and precautions to be followed, or cross-references to these; and
- g. The instructions for storage of the intermediate or API to assure its suitability for use, including the labelling and packaging materials and special storage conditions with time limits, where appropriate.

7.5 Batch Production Records (Batch Production and Control Records)

- 7.5.1 Batch production records should be prepared for each intermediate and API and should include complete information relating to the production and control of each batch. The batch production record should be checked before issuance to assure that it is the correct version and a legible accurate reproduction of the appropriate master production instruction. If the batch production record is produced from a separate part of the master document, that document should include a reference to the current master production instruction being used.
- 7.5.2 These records should be numbered with a unique batch or identification number, dated and signed when issued. In continuous production, the product code together with the date and time can serve as the unique identifier until the final number is allocated.
- 7.5.3 Documentation of completion of each significant step in the batch production records (batch production and control records) should include:
 - a. Dates and, when appropriate, times;
 - b. Identity of major equipment (e.g., reactors, driers, mills, etc.) used;
 - c. Specific identification of each batch, including weights, measures, and batch numbers of raw materials, intermediates, or any reprocessed materials used during manufacturing;

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

- d. Actual results recorded for critical process parameters;
- e. Any sampling performed;
- f. Signatures of the persons performing and directly supervising or checking each critical step in the operation;
- g. In-process and laboratory test results;
- h. Actual yield at appropriate phases or times;
- i. Description of packaging and label for intermediate or API;
- j. Representative label of API or intermediate if made commercially available;
- k. Any deviation noted, its evaluation, investigation conducted (if appropriate) or reference to that investigation if stored separately; and
- l. Results of release testing.

7.5.4 Written procedures should be established and followed for investigating critical deviations or the failure of a batch of intermediate or API to meet specifications. The investigation should extend to other batches that may have been associated with the specific failure or deviation.

7.6 Laboratory Control Records

7.6.1 Laboratory control records should include complete data derived from all tests conducted to ensure compliance with established specifications and standards, including examinations and assays, as follows:

- a. A description of samples received for testing, including the material name or source, batch number or other distinctive code, date sample was taken, and, where appropriate, the quantity and date the sample was received for testing;
- b. A statement of or reference to each test method used;
- c. A statement of the weight or measure of sample used for each test as described by the method; data on or cross-reference to the preparation and testing of reference standards, reagents and standard solutions,
- d. A complete record of all raw data generated during each test, in addition to graphs, charts, and spectra from laboratory instrumentation, properly identified to show the specific material and batch tested;
- e. A record of all calculations performed in connection with the test, including, for example, units of measure, conversion factors, and equivalency factors;

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

- f. A statement of the test results and how they compare with established acceptance criteria;
- g. The signature of the person who performed each test and the date(s) the tests were performed; and
- h. The date and signature of a second person showing that the original records have been reviewed for accuracy, completeness, and compliance with established standards.

7.6.2 Complete records should also be maintained for:

- a. Any modifications to an established analytical method,
- b. Periodic calibration of laboratory instruments, apparatus, gauges, and recording devices;
- c. All stability testing performed on APIs; and
- d. Out-of-specification (OOS) investigations.

7.7 Batch Production Record Review

- 7.7.1 Written procedures should be established and followed for the review and approval of batch production and laboratory control records, including packaging and labelling, to determine compliance of the intermediate or API with established specifications before a batch is released or distributed.
- 7.7.2 Batch production and laboratory control records of critical process steps should be reviewed and approved by the quality unit(s) before an API batch is released or distributed. Production and laboratory control records of non-critical process.
- 7.7.3 steps can be reviewed by qualified production personnel or other units following procedures approved by the quality unit(s).
- 7.7.4 All deviation, investigation, and OOS reports should be reviewed as part of the batch record review before the batch is released.
- 7.7.5 The quality unit(s) can delegate to the production unit the responsibility and authority for release of intermediates, except for those shipped outside the control of the manufacturing company.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

CHAPTER 8: MATERIALS MANAGEMENT

8.1 General Controls

- 8.1.1 There should be written procedures describing the receipt, identification, quarantine, storage, handling, sampling, testing, and approval or rejection of materials.
- 8.1.2 Manufacturers of intermediates and/or APIs should have a system for evaluating the suppliers of critical materials.
- 8.1.3 Materials should be purchased against an agreed specification, from a supplier or suppliers approved by the quality unit(s).
- 8.1.4 If the supplier of a critical material is not the manufacturer of that material, the name and address of that manufacturer should be known by the intermediate and/or API manufacturer.
- 8.1.5 Changing the source of supply of critical raw materials should be treated according to Section 14, Change Control.

8.2 Receipt and Quarantine

- 8.2.1 Upon receipt and before acceptance, each container or grouping of containers of materials should be examined visually for correct labelling (including correlation between the name used by the supplier and the in-house name, if these are different), container damage, broken seals and evidence of tampering or contamination. Materials should be held under quarantine until they have been sampled, examined or tested as appropriate, and released for use.
- 8.2.2 Before incoming materials are mixed with existing stocks (e.g., solvents or stocks in silos), they should be identified as correct, tested, if appropriate, and released. Procedures should be available to prevent discharging incoming materials wrongly into the existing stock.
- 8.2.3 If bulk deliveries are made in non-dedicated tankers, there should be assurance of no cross-contamination from the tanker. Means of providing this assurance could include one or more of the following:
- a. certificate of cleaning
 - b. testing for trace impurities
 - c. audit of the supplier.
- 8.2.4 Large storage containers, and their attendant manifolds, filling and discharge lines should be appropriately identified.
- 8.2.5 Each container or grouping of containers (batches) of materials should be assigned and identified with a distinctive code, batch, or receipt number. This number should be used in

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

recording the disposition of each batch. A system should be in place to identify the status of each batch.

8.3 Sampling and Testing of Incoming Production Materials

8.3.1 At least one test to verify the identity of each batch of material should be conducted, with the exception of the materials described below in 8.3.2. A supplier's Certificate of Analysis can be used in place of performing other tests, provided that the manufacturer has a system in place to evaluate suppliers.

8.3.2 Supplier approval should include an evaluation that provides adequate evidence (e.g., past quality history) that the manufacturer can consistently provide material meeting specifications. Full analyses should be conducted on at least three batches before reducing in-house testing. However, as a minimum, a full analysis should be performed at appropriate intervals and compared with the Certificates of Analysis. Reliability of Certificates of Analysis should be checked at regular intervals.

8.3.3 Processing aids, hazardous or highly toxic raw materials, other special materials, or materials transferred to another unit within the company's control do not need to be tested if the manufacturer's Certificate of Analysis is obtained, showing that these raw materials conform to established specifications. Visual examination of containers, labels, and recording of batch numbers should help in establishing the identity of these materials. The lack of on-site testing for these materials should be justified and documented.

8.3.4 Samples should be representative of the batch of material from which they are taken. Sampling methods should specify the number of containers to be sampled, which part of the container to sample, and the amount of material to be taken from each container. The number of containers to sample and the sample size should be based upon a sampling plan that takes into consideration the criticality of the material, material variability, past quality history of the supplier, and the quantity needed for analysis.

8.3.5 Sampling should be conducted at defined locations and by procedures designed to prevent contamination of the material sampled and contamination of other materials.

8.3.6 Containers from which samples are withdrawn should be opened carefully and subsequently reclosed. They should be marked to indicate that a sample has been taken.

8.4 Storage

8.4.1 Materials should be handled and stored in a manner to prevent degradation, contamination, and cross-contamination.

8.4.2 Materials stored in fiber drums, bags, or boxes should be stored off the floor and, when appropriate, suitably spaced to permit cleaning and inspection.

8.4.3 Materials should be stored under conditions and for a period that have no adverse effect on

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

their quality, and should normally be controlled so that the oldest stock is used first.

8.4.4 Certain materials in suitable containers can be stored outdoors, provided identifying labels remain legible and containers are appropriately cleaned before opening and use.

8.4.5 Rejected materials should be identified and controlled under a quarantine system designed to prevent their unauthorized use in manufacturing.

8.5 Re-evaluation

Materials should be re-evaluated as appropriate to determine their suitability for use (e.g., after prolonged storage or exposure to heat or humidity).

CHAPTER 9: PRODUCTION AND IN-PROCESS CONTROLS

9.1 Production Operations

9.1.1 Raw materials for intermediate and API manufacturing should be weighed or measured under appropriate conditions that do not affect their suitability for use. Weighing and measuring devices should be of suitable accuracy for the intended use.

9.1.2 If a material is subdivided for later use in production operations, the container receiving the material should be suitable and should be so identified that the following information is available:

- a. Material name and/or item code;
- b. Receiving or control number;
- c. Weight or measure of material in the new container; and
- d. Re-evaluation or retest date if appropriate.

9.1.3 Critical weighing, measuring, or subdividing operations should be witnessed or subjected to an equivalent control. Prior to use, production personnel should verify that the materials are those specified in the batch record for the intended intermediate or API.

9.1.4 Other critical activities should be witnessed or subjected to an equivalent control.

9.1.5 Actual yields should be compared with expected yields at designated steps in the production process. Expected yields with appropriate ranges should be established based on previous laboratory, pilot scale, or manufacturing data. Deviations in yield associated with critical process steps should be investigated to determine their impact or potential impact on the resulting quality of affected batches.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

- 9.1.6 Any deviation should be documented and explained. Any critical deviation should be investigated.
- 9.1.7 The processing status of major units of equipment should be indicated either on the individual units of equipment or by appropriate documentation, computer control systems, or alternative means.
- 9.1.8 Materials to be reprocessed or reworked should be appropriately controlled to prevent unauthorized use.

9.2 Time Limits

- 9.2.1 If time limits are specified in the master production instruction (see 7.4.1), these time limits should be met to ensure the quality of intermediates and APIs. Deviations should be documented and evaluated. Time limits may be inappropriate when processing to a target value (e.g., pH adjustment, hydrogenation, drying to predetermined specification) because completion of reactions or processing steps are determined by in-process sampling and testing.
- 9.2.2 Intermediates held for further processing should be stored under appropriate conditions to ensure their suitability for use.

9.3 In-process Sampling and Controls

- 9.3.1 Written procedures should be established to monitor the progress and control the performance of processing steps that cause variability in the quality characteristics of intermediates and APIs. In-process controls and their acceptance criteria should be defined based on the information gained during the development stage or historical data.
- 9.3.2 The acceptance criteria and type and extent of testing can depend on the nature of the intermediate or API being manufactured, the reaction or process step being conducted, and the degree to which the process introduces variability in the product's quality. Less stringent in-process controls may be appropriate in early processing steps, whereas tighter controls may be appropriate for later processing steps (e.g., isolation and purification steps).
- 9.3.3 Critical in-process controls (and critical process monitoring), including the control points and methods, should be stated in writing and approved by the quality unit(s).
- 9.3.4 In-process controls can be performed by qualified production department personnel and the process adjusted without prior quality unit(s) approval if the adjustments are made within pre-established limits approved by the quality unit(s). All tests and results should be fully documented as part of the batch record.
- 9.3.5 Written procedures should describe the sampling methods for in-process materials, intermediates, and APIs. Sampling plans and procedures should be based on scientifically sound sampling practices.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

9.3.6 In-process sampling should be conducted using procedures designed to prevent contamination of the sampled material and other intermediates or APIs. Procedures should be established to ensure the integrity of samples after collection.

9.3.7 Out-of-specification (OOS) investigations are not normally needed for in-process tests that are performed for the purpose of monitoring and/or adjusting the process.

9.4 Blending Batches of Intermediates or APIs

9.4.1 For the purpose of this document, blending is defined as the process of combining materials within the same specification to produce a homogeneous intermediate or API. In-process mixing of fractions from single batches (e.g., collecting several centrifuge loads from a single crystallization batch) or combining fractions from several batches for further processing is considered to be part of the production process and is not considered to be blending.

9.4.2 Out-Of-Specification batches should not be blended with other batches for the purpose of meeting specifications. Each batch incorporated into the blend should have been manufactured using an established process and should have been individually tested and found to meet appropriate specifications prior to blending.

9.4.3 Acceptable blending operations include but are not limited to:

- a. Blending of small batches to increase batch size
- b. Blending of tailings (i.e., relatively small quantities of isolated material) from batches of the same intermediate or API to form a single batch.

9.4.4 Blending processes should be adequately controlled and documented and the blended batch should be tested for conformance to established specifications where appropriate.

9.4.5 The batch record of the blending process should allow traceability back to the individual batches that make up the blend.

9.4.6 Where physical attributes of the API are critical (e.g., APIs intended for use in solid oral dosage forms or suspensions), blending operations should be validated to show homogeneity of the combined batch. Validation should include testing of critical attributes (e.g., particle size distribution, bulk density, and tap density) that may be affected by the blending process.

9.4.7 If the blending could adversely affect stability, stability testing of the final blended batches should be performed.

9.4.8 The expiry or retest date of the blended batch should be based on the manufacturing date of the oldest tailings or batch in the blend.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

9.5 Contamination Control

- 9.5.1 Residual materials can be carried over into successive batches of the same intermediate or API if there is adequate control. Examples include residue adhering to the wall of a micronized, residual layer of damp crystals remaining in a centrifuge bowl after discharge, and incomplete discharge of fluids or crystals from a processing vessel upon transfer of the material to the next step in the process. Such carryover should not result in the carryover of degradants or microbial contamination that may adversely alter the established API impurity profile.
- 9.5.2 Production operations should be conducted in a manner that will prevent contamination of intermediates or APIs by other materials.
- 9.5.3 Precautions to avoid contamination should be taken when APIs are handled after purification.

CHAPTER 10: PACKAGING AND IDENTIFICATION LABELLING OF APIS AND INTERMEDIATES

10.1 General

- 10.1.1 There should be written procedures describing the receipt, identification, quarantine, sampling, examination and/or testing and release, and handling of packaging and labelling materials.
- 10.1.2 Packaging and labelling materials should conform to established specifications. Those that do not comply with such specifications should be rejected to prevent their use in operations for which they are unsuitable.
- 10.1.3 Records should be maintained for each shipment of labels and packaging materials showing receipt, examination, or testing, and whether accepted or rejected.

10.2 Packaging Materials

- 10.2.1 Containers should provide adequate protection against deterioration or contamination of the intermediate or API that may occur during transportation and recommended storage.
- 10.2.2 Containers should be clean and, where indicated by the nature of the intermediate or API, sanitized to ensure that they are suitable for their intended use. These containers should not be reactive, additive, or absorptive so as to alter the quality of the intermediate or API beyond the specified limits.
- 10.2.3 If containers are re-used, they should be cleaned in accordance with documented procedures and all previous labels should be removed or defaced.

10.3 Label Issuance and Control

- 10.3.1 Access to the label storage areas should be limited to authorized personnel.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

- 10.3.2 Procedures should be used to reconcile the quantities of labels issued, used, and returned and to evaluate discrepancies found between the number of containers labelled and the number of labels issued. Such discrepancies should be investigated, and the investigation should be approved by the quality unit(s).
- 10.3.3 All excess labels bearing batch numbers or other batch-related printing should be destroyed. Returned labels should be maintained and stored in a manner that prevents mix-ups and provides proper identification.
- 10.3.4 Obsolete and outdated labels should be destroyed.
- 10.3.5 Printing devices used to print labels for packaging operations should be controlled to ensure that all imprinting conforms to the print specified in the batch production record.
- 10.3.6 Printed labels issued for a batch should be carefully examined for proper identity and conformity to specifications in the master production record. The results of this examination should be documented.
- 10.3.7 A printed label representative of those used should be included in the batch production record.

10.4 Packaging and Labelling Operations

- 10.4.1 There should be documented procedures designed to ensure that correct packaging materials and labels are used.
- 10.4.2 Labelling operations should be designed to prevent mix-ups. There should be physical or spatial separation from operations involving other intermediates or APIs.
- 10.4.3 Labels used on containers of intermediates or APIs should indicate the name or identifying code, the batch number of the product, and storage conditions, when such information is critical to assure the quality of intermediate or API.
- 10.4.4 If the intermediate or API is intended to be transferred outside the control of the manufacturer's material management system, the name and address of the manufacturer, quantity of contents, and special transport conditions and any special legal requirements should also be included on the label. For intermediates or APIs with an expiry date, the expiry date should be indicated on the label and Certificate of Analysis. For intermediates or APIs with a retest date, the retest date should be indicated on the label and/or Certificate of Analysis.
- 10.4.5 Packaging and labelling facilities should be inspected immediately before use to ensure that all materials not needed for the next packaging operation have been removed. This examination should be documented in the batch production records, the facility log, or other documentation system.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

- 10.4.6 Packaged and labelled intermediates or APIs should be examined to ensure that containers and packages in the batch have the correct label. This examination should be part of the packaging operation. Results of these examinations should be recorded in the batch production or control records.
- 10.4.7 Intermediate or API containers that are transported outside of the manufacturer's control should be sealed in a manner such that, if the seal is breached or missing, the recipient will be alerted to the possibility that the contents may have been altered.

CHAPTER 11: STORAGE AND DISTRIBUTION

11.1 Warehousing Procedures

- 11.1.1 Facilities should be available for the storage of all materials under appropriate conditions (e.g. controlled temperature and humidity when necessary). Records should be maintained of these conditions if they are critical for the maintenance of material characteristics.
- 11.1.2 Unless there is an alternative system to prevent the unintentional or unauthorized use of quarantined, rejected, returned, or recalled materials, separate storage areas should be assigned for their temporary storage until the decision as to their future use has been taken.

11.2 Distribution Procedures

- 11.2.1 APIs and intermediates should only be released for distribution to third parties after they have been released by the quality unit(s). APIs and intermediates can be transferred under quarantine to another unit under the company's control when authorized by the quality unit(s) and if appropriate controls and documentation are in place.
- 11.2.2 APIs and intermediates should be transported in a manner that does not adversely affect their quality.
- 11.2.3 Special transport or storage conditions for an API or intermediate should be stated on the label.
- 11.2.4 The manufacturer should ensure that the contract acceptor (contractor) for transportation of the API or intermediate knows and follows the appropriate transport and storage conditions.
- 11.2.5 A system should be in place by which the distribution of each batch of intermediate and/or API can be readily determined to permit its recall.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

CHAPTER 12: LABORATORY CONTROLS

12.1 General Controls

- 12.1.1 The independent quality unit(s) should have at its disposal adequate laboratory facilities.
- 12.1.2 There should be documented procedures describing sampling, testing, approval or rejection of materials, and recording and storage of laboratory data. Laboratory records should be maintained in accordance with Section 7.6.
- 12.1.3 All specifications, sampling plans, and test procedures should be scientifically sound and appropriate to ensure that raw materials, intermediates, APIs, and labels and packaging materials conform to established standards of quality and/or purity. Specifications and test procedures should be consistent with those included in the registration/filing. There can be specifications in addition to those in the registration/filing. Specifications, sampling plans, and test procedures, including changes to them, should be drafted by the appropriate organizational unit and reviewed and approved by the quality unit(s).
- 12.1.4 Appropriate specifications should be established for APIs in accordance with accepted standards and consistent with the manufacturing process. The specifications should include a control of the impurities (e.g. organic impurities, inorganic impurities, and residual solvents). If the API has a specification for microbiological purity, appropriate action limits for total microbial counts and objectionable organisms should be established and met. If the API has a specification for endotoxins, appropriate action limits should be established and met.
- 12.1.5 Laboratory controls should be followed and documented at the time of performance. Any departures from the above described procedures should be documented and explained.
- 12.1.6 Any out-of-specification result obtained should be investigated and documented according to a procedure. This procedure should require analysis of the data, assessment of whether a significant problem exists, allocation of the tasks for corrective actions, and conclusions. Any resampling and/or retesting after OOS results should be performed according to a documented procedure.
- 12.1.7 Reagents and standard solutions should be prepared and labelled following written procedures. "Use by" dates should be applied as appropriate for analytical reagents or standard solutions.
- 12.1.8 Primary reference standards should be obtained as appropriate for the manufacture of APIs. The source of each primary reference standard should be documented. Records should be maintained of each primary reference standard's storage and use in accordance with the supplier's recommendations. Primary reference standards obtained from an officially recognized source are normally used without testing if stored under conditions consistent with the supplier's recommendations.
- 12.1.9 Where a primary reference standard is not available from an officially recognized source, an

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

“in-house primary standard” should be established.

12.1.10 Appropriate testing should be performed to establish fully the identity and purity of the primary reference standard. Appropriate documentation of this testing should be maintained.

12.1.11 Secondary reference standards should be appropriately prepared, identified, tested, approved, and stored. The suitability of each batch of secondary reference standard should be determined prior to first use by comparing against a primary reference standard. Each batch of secondary reference standard should be periodically requalified in accordance with a written protocol.

12.2 Testing of Intermediates and APIs

12.2.1 For each batch of intermediate and API, appropriate laboratory tests should be conducted to determine conformance to specifications.

12.2.2 An impurity profile describing the identified and unidentified impurities present in a typical batch produced by a specific controlled production process should normally be established for each API. The impurity profile should include the identity or some qualitative analytical designation (e.g. retention time), the range of each impurity observed, and classification of each identified impurity (e.g. inorganic, organic, solvent). The impurity profile is normally dependent upon the production process and origin of the API. Impurity profiles are normally not necessary for APIs from herbal or animal tissue origin. Biotechnology considerations are covered in ICH Guideline Q6B.

12.2.3 The impurity profile should be compared at appropriate intervals against the impurity profile in the regulatory submission or compared against historical data in order to detect changes to the API resulting from modifications in raw materials, equipment operating parameters, or the production process.

12.2.4 Appropriate microbiological tests should be conducted on each batch of intermediate and API where microbial quality is specified.

12.3 Validation of Analytical Procedures - see Section 13.

12.4 Certificates of Analysis

12.4.1 Authentic Certificates of Analysis should be issued for each batch of intermediate or API on request.

12.4.2 Information on the name of the intermediate or API including where appropriate its grade, the batch number, and the date of release should be provided on the Certificate of Analysis. For intermediates or APIs with an expiry date, the expiry date should be provided on the label and Certificate of Analysis. For intermediates or APIs with a retest date, the retest date should be indicated on the label and/or Certificate of Analysis.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

- 12.4.3 The Certificate should list each test performed in accordance with compendial or customer requirements, including the acceptance limits, and the numerical results obtained (if test results are numerical).
- 12.4.4 Certificates should be dated and signed by authorised personnel of the quality unit(s) and should show the name, address and telephone number of the original manufacturer. Where the analysis has been carried out by a repacker or reprocessor, the Certificate of Analysis should show the name, address and telephone number of the repacker/reprocessor and a reference to the name of the original manufacturer.
- 12.4.5 If new Certificates are issued by or on behalf of repackers/reprocessors, agents or brokers, these Certificates should show the name, address and telephone number of the laboratory that performed the analysis. They should also contain a reference to the name and address of the original manufacturer and to the original batch Certificate, a copy of which should be attached.

12.5 Stability Monitoring of APIs

- 12.5.1 A documented, on-going testing program should be designed to monitor the stability characteristics of APIs, and the results should be used to confirm appropriate storage conditions and retest or expiry dates.
- 12.5.2 The test procedures used in stability testing should be validated and be stability indicating.
- 12.5.3 Stability samples should be stored in containers that simulate the market container. For example, if the API is marketed in bags within fiber drums, stability samples can be packaged in bags of the same material and in smaller-scale drums of similar or identical material composition to the market drums.
- 12.5.4 Normally the first three commercial production batches should be placed on the stability monitoring program to confirm the retest or expiry date. However, where data from previous studies show that the API is expected to remain stable for at least two years, fewer than three batches can be used.
- 12.5.5 Thereafter, at least one batch per year of API manufactured (unless none is produced that year) should be added to the stability monitoring program and tested at least annually to confirm the stability.
- 12.5.6 For APIs with short shelf-lives, testing should be done more frequently. For example, for those biotechnological/biologic and other APIs with shelf-lives of one year or less, stability samples should be obtained and should be tested monthly for the first three months, and at three-month intervals after that. When data exist that confirm that the stability of the API is not compromised, elimination of specific test intervals (e.g. 9-month testing) can be considered.
- 12.5.7 Where appropriate, the stability storage conditions should be consistent with the ICH

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

Guidelines on stability.

12.6 Expiry and Retest Dating

- 12.6.1 When an intermediate is intended to be transferred outside the control of the manufacturer's material management system and an expiry or retest date is assigned, supporting stability information should be available (e.g. published data, test results).
- 12.6.2 An API expiry or retest date should be based on an evaluation of data derived from stability studies. Common practice is to use a retest date, not an expiration date.
- 12.6.3 Preliminary API expiry or retest dates can be based on pilot scale batches if (1) the pilot batches employ a method of manufacture and procedure that simulates the final process to be used on a commercial manufacturing scale; and (2) the quality of the API represents the material to be made on a commercial scale.
- 12.6.4 A representative sample should be taken for the purpose of performing a retest.

12.7 Reserve/Retention Samples

- 12.7.1 The packaging and holding of reserve samples is for the purpose of potential future evaluation of the quality of batches of API and not for future stability testing purposes.
- 12.7.2 Appropriately identified reserve samples of each API batch should be retained for one year after the expiry date of the batch assigned by the manufacturer, or for three years after distribution of the batch, whichever is the longer. For APIs with retest dates, similar reserve samples should be retained for three years after the batch is completely distributed by the manufacturer.
- 12.7.3 The reserve sample should be stored in the same packaging system in which the API is stored or in one that is equivalent to or more protective than the marketed packaging system. Sufficient quantities should be retained to conduct at least two full compendial analyses or, when there is no pharmacopoeial monograph, two full specification analyses.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

CHAPTER 13: VALIDATION

13.1 Validation Policy

- 13.1.1 The company's overall policy, intentions, and approach to validation, including the validation of production processes, cleaning procedures, analytical methods, in-process control test procedures, computerized systems, and persons responsible for design, review, approval and documentation of each validation phase, should be documented.
- 13.1.2 The critical parameters/attributes should normally be identified during the development stage or from historical data, and the ranges necessary for the reproducible operation should be defined. This should include:
- a. Defining the API in terms of its critical product attributes;
 - b. Identifying process parameters that could affect the critical quality attributes of the API;
 - c. Determining the range for each critical process parameter expected to be used during routine manufacturing and process control.

Validation should extend to those operations determined to be critical to the quality and purity of the API.

13.2 Validation Documentation

- 13.2.1 A written validation protocol should be established that specifies how validation of a particular process will be conducted. The protocol should be reviewed and approved by the quality unit(s) and other designated units.
- 13.2.2 The validation protocol should specify critical process steps and acceptance criteria as well as the type of validation to be conducted (e.g. retrospective, prospective, concurrent) and the number of process runs.
- 13.2.3 A validation report that cross-references the validation protocol should be prepared, summarizing the results obtained, commenting on any deviations observed, and drawing the appropriate conclusions, including recommending changes to correct deficiencies.
- 13.2.4 Any variations from the validation protocol should be documented with appropriate justification.

13.3 Qualification

- 13.3.1 Before starting process validation activities, appropriate qualification of critical equipment and ancillary systems should be completed. Qualification is usually carried out by conducting the following activities, individually or combined:

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

- a. Design Qualification (DQ): documented verification that the proposed design of the facilities, equipment, or systems is suitable for the intended purpose.
- b. Installation Qualification (IQ): documented verification that the equipment or systems, as installed or modified, comply with the approved design, the manufacturer's recommendations and/or user requirements.
- c. Operational Qualification (OQ): documented verification that the equipment or systems, as installed or modified, perform as intended throughout the anticipated operating ranges.
- d. Performance Qualification (PQ): documented verification that the equipment and ancillary systems, as connected together, can perform effectively and reproducibly based on the approved process method and specifications.

13.4 Approaches to Process Validation

- 13.4.1 Process Validation (PV) is the documented evidence that the process, operated within established parameters, can perform effectively and reproducibly to produce an intermediate or API meeting its predetermined specifications and quality attributes.
- 13.4.2 There are three approaches to validation. Prospective validation is the preferred approach, but there are exceptions where the other approaches can be used. These approaches and their applicability are listed below.
- 13.4.3 Prospective validation should normally be performed for all API processes. Prospective validation performed on an API process should be completed before the commercial distribution of the final drug product manufactured from that API.
- 13.4.4 Concurrent validation can be conducted when data from replicate production runs are unavailable because only a limited number of API batches have been produced, API batches are produced infrequently, or API batches are produced by a validated process that has been modified. Prior to the completion of concurrent validation, batches can be released and used in final drug product for commercial distribution based on thorough monitoring and testing of the API batches.
- 13.4.5 An exception can be made for retrospective validation for well-established processes that have been used without significant changes to API quality due to changes in raw materials, equipment, systems, facilities, or the production process. This validation approach may be used where:
- 13.4.6 Critical quality attributes and critical process parameters have been identified;
- 13.4.7 Appropriate in-process acceptance criteria and controls have been established;
- 13.4.8 There have not been significant process/product failures attributable to causes other than operator error or equipment failures unrelated to equipment suitability; and

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

13.4.9 Impurity profiles have been established for the existing API.

13.4.10 Batches selected for retrospective validation should be representative of all batches made during the review period, including any batches that failed to meet specifications, and should be sufficient in number to demonstrate process consistency. Retained samples can be tested to obtain data to retrospectively validate the process.

13.5 Process Validation Program

13.5.1 The number of process runs for validation should depend on the complexity of the process or the magnitude of the process change being considered. For prospective and concurrent validation, three consecutive successful production batches should be used as a guide, but there may be situations where additional process runs are warranted to prove consistency of the process (e.g., complex API processes or API processes with prolonged completion times). For retrospective validation, generally data from ten to thirty consecutive batches should be examined to assess process consistency, but fewer batches can be examined if justified.

13.5.2 Critical process parameters should be controlled and monitored during process validation studies. Process parameters unrelated to quality, such as variables controlled to minimize energy consumption or equipment use, need not be included in the process validation.

13.5.3 Process validation should confirm that the impurity profile for each API is within the limits specified. The impurity profile should be comparable to or better than historical data and, where applicable, the profile determined during process development or for batches used for pivotal clinical and toxicological studies.

13.6 Periodic Review of Validated Systems

Systems and processes should be periodically evaluated to verify that they are still operating in a valid manner. Where no significant changes have been made to the system or process, and a quality review confirms that the system or process is consistently producing material meeting its specifications, there is normally no need for revalidation.

13.7 Cleaning Validation

13.7.1 Cleaning procedures should normally be validated. In general, cleaning validation should be directed to situations or process steps where contamination or carryover of materials poses the greatest risk to API quality. For example, in early production it may be unnecessary to validate equipment cleaning procedures where residues are removed by subsequent purification steps.

13.7.2 Validation of cleaning procedures should reflect actual equipment usage patterns. If various APIs or intermediates are manufactured in the same equipment and the equipment is cleaned by the same process, a representative intermediate or API can be selected for cleaning validation. This selection should be based on the solubility and difficulty of cleaning and the calculation of residue limits based on potency, toxicity, and stability.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

- 13.7.3 The cleaning validation protocol should describe the equipment to be cleaned, procedures, materials, acceptable cleaning levels, parameters to be monitored and controlled, and analytical methods. The protocol should also indicate the type of samples to be obtained and how they are collected and labelled.
- 13.7.4 Sampling should include swabbing, rinsing, or alternative methods (e.g., direct extraction), as appropriate, to detect both insoluble and soluble residues. The sampling methods used should be capable of quantitatively measuring levels of residues remaining on the equipment surfaces after cleaning. Swab sampling may be impractical when product contact surfaces are not easily accessible due to equipment design and/or process limitations (e.g., inner surfaces of hoses, transfer pipes, reactor tanks with small ports or handling toxic materials, and small intricate equipment such as micronizers and microfluidizers).
- 13.7.5 Validated analytical methods having sensitivity to detect residues or contaminants should be used. The detection limit for each analytical method should be sufficiently sensitive to detect the established acceptable level of the residue or contaminant. The method's attainable recovery level should be established. Residue limits should be practical, achievable, verifiable and based on the most deleterious residue. Limits can be established based on the minimum known pharmacological, toxicological, or physiological activity of the API or its most deleterious component.
- 13.7.6 Equipment cleaning/sanitization studies should address microbiological and endotoxin contamination for those processes where there is a need to reduce total microbiological count or endotoxins in the API, or other processes where such contamination could be of concern (e.g., non-sterile APIs used to manufacture sterile products).
- 13.7.7 Cleaning procedures should be monitored at appropriate intervals after validation to ensure that these procedures are effective when used during routine production. Equipment cleanliness can be monitored by analytical testing and visual examination, where feasible. Visual inspection can allow detection of gross contamination concentrated in small areas that could otherwise go undetected by sampling and/or analysis.

13.8 Validation of Analytical Methods

- 13.8.1 Analytical methods should be validated unless the method employed is included in the relevant pharmacopoeia or other recognised standard reference. The suitability of all testing methods used should nonetheless be verified under actual conditions of use and documented.
- 13.8.2 Methods should be validated to include consideration of characteristics included within the ICH Guidelines on validation of analytical methods. The degree of analytical validation performed should reflect the purpose of the analysis and the stage of the API production process.
- 13.8.3 Appropriate qualification of analytical equipment should be considered before starting validation of analytical methods.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

- 13.8.4 Complete records should be maintained of any modification of a validated analytical method. Such records should include the reason for the modification and appropriate data to verify that the modification produces result that are as accurate and reliable as the established method.

CHAPTER 14: CHANGE CONTROL

- 14.1 A formal change control system should be established to evaluate all changes that may affect the production and control of the intermediate or API.
- 14.2 Written procedures should provide for the identification, documentation, appropriate review, and approval of changes in raw materials, specifications, analytical methods, facilities, support systems, equipment (including computer hardware), processing steps, labelling and packaging materials, and computer software.
- 14.3 Any proposals for GMP relevant changes should be drafted, reviewed, and approved by the appropriate organisational units, and reviewed and approved by the quality unit(s).
- 14.4 The potential impact of the proposed change on the quality of the intermediate or API should be evaluated. A classification procedure may help in determining the level of testing, validation, and documentation needed to justify changes to a validated process. Changes can be classified (e.g. as minor or major) depending on the nature and extent of the changes, and the effects these changes may impact on the process. Scientific judgement should determine what additional testing and validation studies are appropriate to justify a change in a validated process.
- 14.5 When implementing approved changes, measures should be taken to ensure that all documents affected by the changes are revised.
- 14.6 After the change has been implemented, there should be an evaluation of the first batches produced or tested under the change.
- 14.7 The potential for critical changes to affect established retest or expiry dates should be evaluated. If necessary, samples of the intermediate or API produced by the modified process can be placed on an accelerated stability program and/or can be added to the stability monitoring program.
- 14.8 Current dosage form manufacturers should be notified of changes from established production and process control procedures that can impact the quality of the API.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

CHAPTER 15: REJECTION AND RE-USE OF MATERIALS

15.1 Rejection

Intermediates and APIs failing to meet established specifications should be identified as such and quarantined. These intermediates or APIs can be reprocessed or reworked as described below. The final disposition of rejected materials should be recorded.

15.2 Reprocessing

15.2.1 Introducing an intermediate or API, including one that does not conform to standards or specifications, back into the process and reprocessing by repeating a crystallization step or other appropriate chemical or physical manipulation steps (e.g., distillation, filtration, chromatography, milling) that are part of the established manufacturing process is generally considered acceptable. However, if such reprocessing is used for a majority of batches, such reprocessing should be included as part of the standard manufacturing process.

15.2.2 Continuation of a process step after an in-process control test has shown that the step is incomplete is considered to be part of the normal process. This is not considered to be reprocessing.

15.2.3 Introducing unreacted material back into a process and repeating a chemical reaction is considered to be reprocessing unless it is part of the established process. Such reprocessing should be preceded by careful evaluation to ensure that the quality of the intermediate or API is not adversely impacted due to the potential formation of by-products and over-reacted materials.

15.3 Reworking

15.3.1 Before a decision is taken to rework batches that do not conform to established standards or specifications, an investigation into the reason for non-conformance should be performed.

15.3.2 Batches that have been reworked should be subjected to appropriate evaluation, testing, stability testing if warranted, and documentation to show that the reworked product is of equivalent quality to that produced by the original process. Concurrent validation is often the appropriate validation approach for rework procedures. This allows a protocol to define the rework procedure, how it will be carried out, and the expected results. If there is only one batch to be reworked, then a report can be written and the batch released once it is found to be acceptable.

15.3.3 Procedures should provide for comparing the impurity profile of each reworked batch against batches manufactured by the established process. Where routine analytical methods are inadequate to characterize the reworked batch, additional methods should be used.

15.4 Recovery of Materials and Solvents

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

- 15.4.1 Recovery (e.g. from mother liquor or filtrates) of reactants, intermediates, or the API is considered acceptable, provided that approved procedures exist for the recovery and the recovered materials meet specifications suitable for their intended use.
- 15.4.2 Solvents can be recovered and reused in the same processes or in different processes, provided that the recovery procedures are controlled and monitored to ensure that solvents meet appropriate standards before reuse or co-mingling with other approved materials.
- 15.4.3 Fresh and recovered solvents and reagents can be combined if adequate testing has shown their suitability for all manufacturing processes in which they may be used.
- 15.4.4 The use of recovered solvents, mother liquors, and other recovered materials should be adequately documented.

15.5 Returns

- 15.5.1 Returned intermediates or APIs should be identified as such and quarantined.
- 15.5.2 If the conditions under which returned intermediates or APIs have been stored or shipped before or during their return or the condition of their container's casts doubt on their quality, the returned intermediates or APIs should be reprocessed, reworked, or destroyed, as appropriate.
- 15.5.3 Records of returned intermediates or APIs should be maintained. For each return, documentation should include:
- Name and address of the consignee
 - Intermediate or API, batch number, and quantity contract Manufacturers (Including Laboratories)
 - Reason for return
 - Use or disposal of the returned intermediate or API

CHAPTER 16: COMPLAINTS AND RECALLS

- 16.1 All quality related complaints, whether received orally or in writing, should be recorded and investigated according to a written procedure.
- 16.2 Complaint records should include:
- Name and address of complainant;
 - Name (and, where appropriate, title) and phone number of person submitting the complaint;
 - Complaint nature (including name and batch number of the API);

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

- d. Date complaint is received;
- e. Action initially taken (including dates and identity of person taking the action);
- f. Any follow-up action taken;
- g. Response provided to the originator of complaint (including date response sent); and
- h. Final decision on intermediate or API batch or lot.

- 16.3 Records of complaints should be retained in order to evaluate trends, product- related frequencies, and severity with a view to taking additional, and if appropriate, immediate corrective action.
- 16.4 There should be a written procedure that defines the circumstances under which a recall of an intermediate or API should be considered.
- 16.5 The recall procedure should designate who should be involved in evaluating the information, how a recall should be initiated, who should be informed about the recall, and how the recalled material should be treated.
- 16.6 In the event of a serious or potentially life-threatening situation, local, national, and/or international authorities should be informed and their advice sought.

CHAPTER 17: CONTRACT MANUFACTURERS (INCLUDING LABORATORIES)

- 17.1 All contract manufacturers (including laboratories) should comply with the GMP defined in this Guide. Special consideration should be given to the prevention of cross-contamination and to maintaining traceability.
- 17.2 Contract manufacturers (including laboratories) should be evaluated by the contract giver to ensure GMP compliance of the specific operations occurring at the contract sites.
- 17.3 There should be a written and approved contract or formal agreement between the contract giver and the contract acceptor that defines in detail the GMP responsibilities, including the quality measures, of each party.
- 17.4 The contract should permit the contract giver to audit the contract acceptor's facilities for compliance with GMP.
- 17.5 Where subcontracting is allowed, the contract acceptor should not pass to a third party any of the work entrusted to him under the contract without the contract giver's prior evaluation and approval of the arrangements.
- 17.6 Manufacturing and laboratory records should be kept at the site where the activity occurs and be readily available.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

17.7 Changes in the process, equipment, test methods, specifications, or other contractual requirements should not be made unless the contract giver is informed and approves the changes.

CHAPTER 18: AGENTS, BROKERS, TRADERS, DISTRIBUTORS, REPACKERS AND RELABELLERS

18.1 Applicability

18.1.1 This section applies to any party other than the original manufacturer who may trade and/or take possession, repack, relabel, manipulate, distribute or store an API or intermediate.

18.1.2 All agents, brokers, traders, distributors, repackers, and relabellers should comply with GMP as defined in this Guide.

18.2 Traceability of Distributed APIs and Intermediates

Agents, brokers, traders, distributors, repackers, or relabellers should maintain complete traceability of APIs and intermediates that they distribute. Documents that should be retained and available include:

- a. Identity of original manufacturer
- b. Address of original manufacturer
- c. Purchase orders
- d. Bills of lading (transportation documentation)
- e. Receipt documents
- f. Name or designation of API or intermediate
- g. Manufacturer's batch number
- h. Transportation and distribution records
- i. All authentic Certificates of Analysis, including those of the original manufacturer
- j. Retest or expiry date

18.3 Quality Management

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

Agents, brokers, traders, distributors, repackers, or relabellers should establish, document and implement an effective system of managing quality, as specified in Section 3.

18.4 Repackaging, Relabeling and Holding of APIs and Intermediates

18.4.1 Repackaging, relabeling and holding of APIs and intermediates should be performed under appropriate GMP controls, as stipulated in this Guide, to avoid mix-ups and loss of API or intermediate identity or purity.

18.4.2 Repackaging should be conducted under appropriate environmental conditions to avoid contamination and cross-contamination.

18.5 Stability

Stability studies to justify assigned expiration or retest dates should be conducted if the API or intermediate is repackaged in a different type of container than that used by the API or intermediate manufacturer.

18.6 Transfer of information

18.6.1 Agents, brokers, distributors, repackers, or relabellers should transfer all quality or regulatory information received from an API or intermediate manufacturer to the customer, and from the customer to the API or intermediate manufacturer.

18.6.2 The agent, broker, trader, distributor, repacker, or relabeller who supplies the API or intermediate to the customer should provide the name of the original API or intermediate manufacturer and the batch number(s) supplied.

18.6.3 The agent should also provide the identity of the original API or intermediate manufacturer to regulatory authorities upon request. The original manufacturer can respond to the regulatory authority directly or through its authorized agents, depending on the legal relationship between the authorized agents and the original API or intermediate manufacturer. (In this context "authorized" refers to authorized by the manufacturer.)

18.6.4 The specific guidance for Certificates of Analysis included in Section 12.4 should be met.

18.7 Handling of Complaints and Recalls

Agents, brokers, traders, distributors, repackers, or relabellers should maintain records of complaints and recalls, as specified in Section 16, for all complaints and recalls that come to their attention.

If the situation warrants, the agents, brokers, traders, distributors, repackers, or relabellers should review the complaint with the original API or intermediate manufacturer in order to determine whether any further action, either with other customers who may have received this API or intermediate or with the regulatory authority, or both, should be initiated. The investigation into the cause for the complaint or recall should be conducted and documented by the appropriate party.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

Where a complaint is referred to the original API or intermediate manufacturer, the record maintained by the agents, brokers, traders, distributors, repackers, or relabellers should include any response received from the original API or intermediate manufacturer (including date and information provided).

18.8 Handling of Returns

Returns should be handled as specified in Section 15.5. The agents, brokers, traders, distributors, repackers, or relabellers should maintain documentation of returned APIs and intermediates.

CHAPTER 19: SPECIFIC GUIDANCE FOR APIS MANUFACTURED BY CELL CULTURE/FERMENTATION

19.1 General

19.1.1 Section 19 is intended to address specific controls for APIs or intermediates manufactured by cell culture or fermentation using natural or recombinant organisms and that have not been covered adequately in the previous sections. It is not intended to be a stand-alone Section. In general, the GMP principles in the other sections of this document apply. Note that the principles of fermentation for “classical” processes for production of small molecules and for processes using recombinant and non-recombinant organisms for production of proteins and/or polypeptides are the same, although the degree of control will differ. Where practical, this section will address these differences. In general, the degree of control for biotechnological processes used to produce proteins and polypeptides is greater than that for classical fermentation processes.

19.1.2 The term “biotechnological process” (biotech) refers to the use of cells or organisms that have been generated or modified by recombinant DNA, hybridoma or other technology to produce APIs. The APIs produced by biotechnological processes normally consist of high molecular weight substances, such as proteins and polypeptides, for which specific guidance is given in this Section. Certain APIs of low molecular weight, such as antibiotics, amino acids, vitamins, and carbohydrates, can also be produced by recombinant DNA technology. The level of control for these types of APIs is similar to that employed for classical fermentation.

19.1.3 The term “classical fermentation” refers to processes that use microorganisms existing in nature and/or modified by conventional methods (e.g. irradiation or chemical mutagenesis) to produce APIs. APIs produced by “classical fermentation” are normally low molecular weight products such as antibiotics, amino acids, vitamins, and carbohydrates.

19.1.4 Production of APIs or intermediates from cell culture or fermentation involves biological processes such as cultivation of cells or extraction and purification of material from living organisms. Note that there may be additional process steps, such as physicochemical modification, that are part of the manufacturing process. The raw materials used (media, buffer components) may provide the potential for growth of microbiological contaminants. Depending on the source, method of preparation, and the intended use of the API or

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

intermediate, control of bioburden, viral contamination, and/or endotoxins during manufacturing and monitoring of the process at appropriate stages may be necessary.

19.1.5 Appropriate controls should be established at all stages of manufacturing to assure intermediate and/or API quality. While this Guide starts at the cell culture/fermentation step, prior steps (e.g. cell banking) should be performed under appropriate process controls. This Guide covers cell culture/fermentation from the point at which a vial of the cell bank is retrieved for use in manufacturing.

19.1.6 Appropriate equipment and environmental controls should be used to minimize the risk of contamination. The acceptance criteria for quality of the environment and the frequency of monitoring should depend on the step-in production and the production conditions (open, closed, or contained systems).

19.1.7 In general, process controls should take into account:

- a. Maintenance of the Working Cell Bank (where appropriate);
- b. Proper inoculation and expansion of the culture;
- c. Control of the critical operating parameters during fermentation/cell culture;
- d. Monitoring of the process for cell growth, viability (for most cell culture processes) and productivity where appropriate;
- e. Harvest and purification procedures that remove cells, cellular debris and media components while protecting the intermediate or API from contamination (particularly of a microbiological nature) and from loss of quality;
- f. Monitoring of bioburden and, where needed, endotoxin levels at appropriate stages of production; and
- g. Viral safety concerns as described in ICH Guideline Q5A Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin.

19.1.8 Where appropriate, the removal of media components, host cell proteins, other process-related impurities, product-related impurities and contaminants should be demonstrated.

19.2 Cell Bank Maintenance and Record Keeping

19.2.1 Access to cell banks should be limited to authorized personnel.

19.2.2 Cell banks should be maintained under storage conditions designed to maintain viability and prevent contamination.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

- 19.2.3 Records of the use of the vials from the cell banks and storage conditions should be maintained.
- 19.2.4 Where appropriate, cell banks should be periodically monitored to determine suitability for use.
- 19.2.5 See ICH Guideline Q5D Quality of Biotechnological Products: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products for a more complete discussion of cell banking.

19.3 Cell Culture/Fermentation

- 19.3.1 Where aseptic addition of cell substrates, media, buffers, and gases is needed, closed or contained systems should be used where possible. If the inoculation of the initial vessel or subsequent transfers or additions (media, buffers) are performed in open vessels, there should be controls and procedures in place to minimize the risk of contamination.
- 19.3.2 Where the quality of the API can be affected by microbial contamination, manipulations using open vessels should be performed in a biosafety cabinet or similarly controlled environment.
- 19.3.3 Personnel should be appropriately gowned and take special precautions handling the cultures.
- 19.3.4 Critical operating parameters (for example temperature, pH, agitation rates, addition of gases, pressure) should be monitored to ensure consistency with the established process. Cell growth, viability (for most cell culture processes), and, where appropriate, productivity should also be monitored. Critical parameters will vary from one process to another, and for classical fermentation, certain parameters (cell viability, for example) may not need to be monitored.
- 19.3.5 Cell culture equipment should be cleaned and sterilized after use. As appropriate, fermentation equipment should be cleaned, and sanitized or sterilized.
- 19.3.6 Culture media should be sterilized before use when appropriate to protect the quality of the API.
- 19.3.7 There should be appropriate procedures in place to detect contamination and determine the course of action to be taken. This should include procedures to determine the impact of the contamination on the product and those to decontaminate the equipment and return it to a condition to be used in subsequent batches. Foreign organisms observed during fermentation processes should be identified as appropriate and the effect of their presence on product quality should be assessed, if necessary. The results of such assessments should be taken into consideration in the disposition of the material produced.
- 19.3.8 Records of contamination events should be maintained.
- 19.3.9 Shared (multi-product) equipment may warrant additional testing after cleaning between product campaigns, as appropriate, to minimize the risk of cross- contamination.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

19.4 Harvesting, Isolation and Purification

- 19.4.1 Harvesting steps, either to remove cells or cellular components or to collect cellular components after disruption, should be performed in equipment and areas designed to minimize the risk of contamination.
- 19.4.2 Harvest and purification procedures that remove or inactivate the producing organism, cellular debris and media components (while minimizing degradation, contamination, and loss of quality) should be adequate to ensure that the intermediate or API is recovered with consistent quality.
- 19.4.3 All equipment should be properly cleaned and, as appropriate, sanitized after use. Multiple successive batching without cleaning can be used if intermediate or API quality is not compromised.
- 19.4.4 If open systems are used, purification should be performed under environmental conditions appropriate for the preservation of product quality.
- 19.4.5 Additional controls, such as the use of dedicated chromatography resins or additional testing, may be appropriate if equipment is to be used for multiple products.

19.5 Viral Removal/Inactivation Steps

- 19.5.1 See the ICH Guideline Q5A *Quality of Biotechnological Products: Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin* for more specific information.
- 19.5.2 Viral removal and viral inactivation steps are critical processing steps for some processes and should be performed within their validated parameters.
- 19.5.3 Appropriate precautions should be taken to prevent potential viral contamination from pre-viral to post-viral removal/inactivation steps. Therefore, open processing should be performed in areas that are separate from other processing activities and have separate air handling units.
- 19.5.4 The same equipment is not normally used for different purification steps. However, if the same equipment is to be used, the equipment should be appropriately cleaned and sanitized before reuse. Appropriate precautions should be taken to prevent potential virus carry-over (e.g. through equipment or environment) from previous steps.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

CHAPTER 20: APIS FOR USE IN CLINICAL TRIALS

20.1 General

- 20.1.1 Not all the controls in the previous sections of this Guide are appropriate for the manufacture of a new API for investigational use during its development. Section 20 provides specific guidance unique to these circumstances.
- 20.1.2 The controls used in the manufacture of APIs for use in clinical trials should be consistent with the stage of development of the drug product incorporating the API. Process and test procedures should be flexible to provide for changes as knowledge of the process increases and clinical testing of a drug product progresses from pre-clinical stages through clinical stages. Once drug development reaches the stage where the API is produced for use in drug products intended for clinical trials, manufacturers should ensure that APIs are manufactured in suitable facilities using appropriate production and control procedures to ensure the quality of the API.

20.2 Quality

- 20.2.1 Appropriate GMP concepts should be applied in the production of APIs for use in clinical trials with a suitable mechanism of approval of each batch.
- 20.2.2 A quality unit(s) independent from production should be established for the approval or rejection of each batch of API for use in clinical trials.
- 20.2.3 Some of the testing functions commonly performed by the quality unit(s) can be performed within other organizational units.
- 20.2.4 Quality measures should include a system for testing of raw materials, packaging materials, intermediates, and APIs.
- 20.2.5 Process and quality problems should be evaluated.
- 20.2.6 Labelling for APIs intended for use in clinical trials should be appropriately controlled and should identify the material as being for investigational use.

20.3 Equipment and Facilities

- 20.3.1 During all phases of clinical development, including the use of small-scale facilities or laboratories to manufacture batches of APIs for use in clinical trials, procedures should be in place to ensure that equipment is calibrated, clean and suitable for its intended use.
- 20.3.2 Procedures for the use of facilities should ensure that materials are handled in a manner that minimizes the risk of contamination and cross-contamination.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

20.4 Control of Raw Materials

- 20.4.1 Raw materials used in production of APIs for use in clinical trials should be evaluated by testing, or received with a supplier's analysis and subjected to identity testing. When a material is considered hazardous, a supplier's analysis should suffice.
- 20.4.2 In some instances, the suitability of a raw material can be determined before use based on acceptability in small-scale reactions (i.e., use testing) rather than on analytical testing alone.

20.5 Production

- 20.5.1 The production of APIs for use in clinical trials should be documented in laboratory notebooks, batch records, or by other appropriate means. These documents should include information on the use of production materials, equipment, processing, and scientific observations.
- 20.5.2 Expected yields can be more variable and less defined than the expected yields used in commercial processes. Investigations into yield variations are not expected.

20.6 Validation

- 20.6.1 Process validation for the production of APIs for use in clinical trials is normally inappropriate, where a single API batch is produced or where process changes during API development make batch replication difficult or inexact. The combination of controls, calibration, and, where appropriate, equipment qualification assures API quality during this development phase.
- 20.6.2 Process validation should be conducted in accordance with Section 13 when batches are produced for commercial use, even when such batches are produced on a pilot or small scale.

20.7 Changes

Changes are expected during development, as knowledge is gained and the production is scaled up. Every change in the production, specifications, or test procedures should be adequately recorded.

20.8 Laboratory Controls

- 20.8.1 While analytical methods performed to evaluate a batch of API for clinical trials may not yet be validated, they should be scientifically sound.
- 20.8.2 A system for retaining reserve samples of all batches should be in place. This system should ensure that a sufficient quantity of each reserve sample is retained for an appropriate length of time after approval, termination, or discontinuation of an application.
- 20.8.3 Expiry and retest dating as defined in Section 12.6 applies to existing APIs used in clinical trials. For new APIs, Section 12.6 does not normally apply in early stages of clinical trials.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

20.9 Documentation

- 20.9.1 A system should be in place to ensure that information gained during the development and the manufacture of APIs for use in clinical trials is documented and available.
- 20.9.2 The development and implementation of the analytical methods used to support the release of a batch of API for use in clinical trials should be appropriately documented.
- 20.9.3 A system for retaining production and control records and documents should be used. This system should ensure that records and documents are retained for an appropriate length of time after the approval, termination, or discontinuation of an application.

CHAPTER 21: CLASSIFICATION OF INSPECTION FINDINGS

Non compliances found during inspections are classified in the following three categories:

21.1 Critical non-compliance: A non-compliance which has produced, or leads to a significant risk of producing either product which is harmful to the human or veterinary patient or a product which could result in a harmful residue in a food producing animal.

21.2 Major non-compliance

A non-critical deficiency:

which has produced or may produce a product, which does not comply with its marketing authorization;

or

which indicates a major deviation from Rwanda FDA Good Manufacturing Practice;

or

which indicates a major deviation from the terms of the manufacturing authorization;

or

which indicates a failure to carry out satisfactory procedures for release of batches

or

a failure of the authorized person to fulfil his/her required duties;

or

a combination of several “other” deficiencies, none of which on their own may be major, but which may together represent a major deficiency and should be explained and reported as such.





21.3 Other non-compliance:

A deficiency which cannot be classified as either critical or major, but which indicates a departure from good manufacturing practice. A non-conformance may be “other” either because it is judged as minor, or because there is insufficient information to classify it as

The categorization of GMP inspection findings will be as described in PIC/S guidance on classification of GMP deficiencies, PI 040-1,3 Appendices,1 January 2019.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023


ENDORSEMENT OF THE GUIDELINES

	Author	Checked by		Approved by
Title	DM/Food and Drugs Inspection and Compliance	HoD/Food and Drugs Inspection and Safety Monitoring	Quality Assurance Analyst	Director General
Names	Dr. Marilyn M. MURINDAHABI	Dr. Eric NYIRIMIGABO	Théogène NDAYAMBAJE	Dr. Emile BIENVENU
Signature				 Digitally signed by Rwanda FDA (Director General) Date: 2023.04.06 10:18:42 +02'00'
Date	03/04/2023	03/04/2023	03/04/2023	06 / 04 / 2023

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

ANNEXES

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023

Format: QMS/FMT/002 Revision No: 1 Effective Date: 20 June 2022	Department/Division/Office/Unit	Food and Drugs Inspection and Compliance Division
Document Type: Form		Doc. No : FDISM/FDIC/FOM/001
	Title: Application form for Good Manufacturing Practice Inspection for Finished Pharmaceutical Products Manufacturing Facilities	Revision Number : 1
		Revision Date: : 29/08/2022
		Effective Date : 30/09/2023
		Review Due Date : 29/09/2025
		Ref Doc. : FDISM/FDIC/GDL/001

ANNEX 1: Application form for GMP inspection for Finished Pharmaceutical Products Manufacturing Facilities

Applicant to fill the following sections

1. Particulars of the Applicant

Name _____
 Physical Address _____
 Country _____ Telephone _____
 E-mail _____

2. Particulars of Manufacturing Site to be Inspected

Name of site _____
 Physical Address (if different from 1. above) _____

 Country _____ Tel _____
 E-mail: _____

Note: Separate application to be filled in for each individual site

3. Contact Person on Site

Name of contact person _____
 Tel: _____ Fax: _____
 E-mail: _____

4. Authorized Representative/Agent in Rwanda

Name of Local Technical Representative _____
 Tel: _____ E-mail: _____

5. Type of Medicines/ Active Pharmaceutical Ingredients

Type of medicines manufactured (*double click to check applicable box*)

Human ☐ Veterinary ☐ Human & Veterinary.... Herbal

6. Registration of Products in Rwanda

Have you registered any products in Rwanda YES ☐ NO ☐

Have you submitted product dossier for registration from the production line(s) applied for inspection? YES ☐ NO ☐ (If "YES", list of the products in the table below)

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

Trade Name (if any)	Generic Name	Dosage Form	Strength	Primary Packaging

7. Inspection Applied for (Double click to check applicable box)

- ☐ First Inspection
☐ Routine Inspection (state previous inspection datesDD/MM/YYYY)
☐ Re-inspection (after failure)
☐ Other (please specify)

8. Major Site Changes Since Last Inspection

Provide summary of changes to personnel, equipment, buildings, specifications, computer systems, products (type, range or category), suppliers and contractors since last inspection, below or as an Attachment to this form.

.....

Production Lines to be Inspected (Please tick or fill in the applicable boxes)

		Yes	No	Building Block name/ number	Number of production lines	Non β -lactam	β -lactam					
							Penicillin	Cephalosporin	Cytotoxic	Hormones	Human	Veterinary
1. MANUFACTURING OPERATIONS												
1.1 Sterile products												
a	Aseptically prepared (list of dosage forms)											
a)	Large volume liquids											
b)	Lyophilisates											
c)	Semi-solids											
d)	Small volume liquids											
e)	Solids and implants											
f)	Other aseptically prepared products (e.g. eye drops, prefilled syringes)											
g)	Terminally sterilized (list of dosage forms)											
h)	Large volume liquids											
i)	Semi-solids											
j)	Small volume liquids											
k)	Solids and implants											
l)	Other terminally sterilised prepared products											
1.2 Non-sterile products (list of dosage forms)												
a)	Capsules, hard shell											
b)	Capsules, soft shell											
c)	Impregnated matrices											

Doc. No.: FDISM/FDIC/GDL/010

Revision Date: 29/03/2023

Review Due Date: 11/04 /2026

Revision No.: 2

Approval date: 06/04 /2023

Effective Date: 12/04/2023

Guidelines on Good Manufacturing Practice for Active Pharmaceutical Products - Part 2

	Ye s	No	Building Block name/ number	Number of productio n lines	Non β- lactam	β-lactam						
						Pen icill in	C ep ha lo sp or in	C yt ot o xi c	H or m o n e s	H u m an	V et er in ar y	
d) Liquids for external use												
e) Liquids for internal use												
f) Dry powders for oral suspension												
g) Medicated lozenges												
h) Powders/granules in sachets												
i) Medicinal gases												
j) Other solid dosage forms (please specify)												
k) Pressurised preparations												
l) Radionuclide generators												
m) Semi-solids												
n) Suppositories												
o) Tablets												
p) Transdermal patches												
m) Intraruminal devices												
n) Veterinary premixes												
o) Other non-sterile medicinal products												
1.3 Biological medicinal products												
a) Blood products												
b) Immunological products												
Vaccines												
Sera												
Other immunological products												
c) Cell therapy products												
d) Gene therapy products												
e) Biotechnology products												
f) Human or animal extracted products												
g) Biosimilar products												
h) Other												
1.4 Other products or manufacturing activity												
Manufacture of:												
a) Herbal products												
b) Homoeopathic products												
c) Biological active starting materials												
d) Active pharmaceutical ingredients (chemical)												
e) Other												
2.0 Sterilisation of active substance/excipients/finished product:												
a) Filtration												
b) Dry heat												

ANNEX 2: Requirements for GMP Inspection Application for Finished Pharmaceutical Products & Active Pharmaceutical Ingredients Manufacturing Facilities

- a. Application letter addressed to DG of Rwanda FDA
- b. Filled and signed application form
- c. Proof of payment of prescribed fees
- d. Site master file (*Annex 14, WHO Technical Report Series, No. 961*) that is not older than one year from its approval date and any forecasted modifications, including legible colored printouts of water treatment, air-handling systems, including pipeline and instrumentation drawings (P&IDs) in A3 or A2 format
- e. Current manufacturing license for foreign facilities and for domestic facilities to attach application form and proof of payment of manufacturing license.
- f. Current GMP Certificate (GLP, ISO/IEC 17025 accreditation Certificate or WHO prequalification for outsourced laboratory)
- g. List of all the products (medicinal or other) manufactured on site and List of products intended for supply in Rwanda. The lists should include proprietary names and international non-proprietary names (INN).

The following documents may be required for the facilities eligible for desk review, virtual inspection and temporary waiver:

- h. Copy of the recent GMP inspection report done by Local medicine regulatory authority and recent GMP inspection report from PIC/S SRA/WLAs or EAC NMRA's if available with a certified translated copy where this is not in English or French or Kinyarwanda.
- i. A copy of any warning letter or equivalent regulatory action issued by any authority to which the site provides or has applied to provide the product.
- j. Corrective and preventive action (CAPA) and proof of CAPA implementation related to the inspection report observations/deficiencies.
- k. The most recent product quality review(s) (PQR)(s) of the concerned product(s)
- l. A confirmation by the senior quality assurance representative that a full self-inspection or external audit dedicated to the product(s) has been performed and all matters dealt with
- m. Quality Manual/Laboratory Manual or equivalent
- n. The completed batch manufacturing/packaging record(s) including the analytical part for the most recent released batch of relevant product(s).
- o. A list of any recalls or any Market complaints register in the last three years.
- p. Aseptic validation report (Required for products applied for that are not terminally sterilized).
- q. Contract or agreement between the FPP or API manufacturer and the outsourced testing laboratory or sterilization institution (for Outsourced testing laboratory; and Outsourced sterilization).
- r. Validation master plan.
- s. Process validation for one of the products marketed or to be registered in the country of import.

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

ANNEX 3: GMP Inspection Report**Rwanda Food and Drugs Authority**

Nyarutarama Plaza, KG 9 Avenue

P.O. Box: 1948 Kigali - Rwanda

Email: info@rwandafda.gov.rwwebsite: www.rwandafda.gov.rw

QMS N°: FDISM/FDIC/FMT/019

Revision No: 1

Effective Date: 30/09/2022

GMP INSPECTION REPORT

Inspection dates:	Report date:
1.0 General Information	
1.1 Inspected Site(s)	
a) Name: b) Physical address: c) City: d) Country:	
e) Telephone: f) Email address :	
g) Manufacturing license number:	
h) Contact person(s) of the inspected site or facility:	
1.2 Activities carried out by the company at the inspected site	
1.3 GMP Inspectors	
Name of Rwanda FDA Lead Inspector:	
Names of Rwanda FDA GMP Inspectors that carried out the inspection:	
1.5 Name of expert if applicable:	
1.6 Foreign National Regulatory Authority Participation:	
1.7 Type of inspection:	
1.8 Purpose of Inspection:	
1.9 Introduction	
1.10 Other manufacturing activities carried out on the site:	
1.11 Use of outside scientific, analytical, or other technical assistance in manufacture and quality control	
1.12 Previous inspections conducted by:	
1.13 Other Regulatory Authorities	
1.14 Major changes since the previous inspection	
1.15 Samples taken and results obtained (if applicable)	
2.0 Brief Report of the Inspection activities undertaken	
2.1 Scope of Inspection	
2.2 Observations and Findings	

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date: 11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date: 12/04/2023

2.2.1 Pharmaceutical Quality System
2.2.2 Personnel
2.2.3 Premises
2.2.4 Utilities
2.2.5 Equipment
2.2.6 Documentation
2.2.7 Good practices in production
2.2.8 Good practices in quality control
2.2.9 Outsourced Activities
2.2.10 Complaints and Product Recalls
2.2.11 Self-Inspection, Quality Audits, Supplier's Audits
3.0 Summary of non-conformances to GMP
4.0 Recommendations and Conclusion
4.1 Recommendations
4.2 Conclusion – inspection outcome

Definition of Non-conformances

NAMES OF THE INSPECTORS AND SIGNATURES

End of Report

End of Document

Doc. No.: FDISM/FDIC/GDL/010	Revision Date: 29/03/2023	Review Due Date:11/04 /2026
Revision No.: 2	Approval date: 06/04 /2023	Effective Date:12/04/2023